

REC'D 07 MAR 2005

WIPO

PCT

PA 1273771

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

January 18, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.


APPLICATION NUMBER: 60/630,777

FILING DATE: *November 23, 2004*

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



P. SWAIN

Certifying Officer



22764 U.S. PTO

PTO/SB/16 (04-04)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. **EU807929945US**

00746 U.S. PTO
60/630777



112304

| INVENTOR(S) | | | | | |
|---|--|--|--------------|--|--------------|
| Given Name (first and middle (if any)) | | Family Name or Surname | | Residence (City and either State or Foreign Country) | |
| RICHARD JOHN JEREMY TYSON | | SCIOTTI STARR | | Saline, MI 48176 Ann Arbor, MI 48105 | |
| Additional inventors are being named on the _____ separately numbered sheets attached hereto | | | | | |
| TITLE OF THE INVENTION (500 characters max) | | | | | |
| Direct all correspondence to: CORRESPONDENCE ADDRESS | | | | | |
| <input checked="" type="checkbox"/> Customer Number: 28880 | | | | | |
| OR | | | | | |
| <input checked="" type="checkbox"/> Firm or Individual Name | | J. Michael Dixon | | | |
| Address | | Pfizer Inc | | | |
| Address | | 2800 Plymouth Road | | | |
| City | | Ann Arbor | | State | MI |
| | | Zip | 48105 | | |
| Country | | U.S.A. | | Telephone | 734-622-1705 |
| | | Fax | 734-622-2928 | | |
| ENCLOSED APPLICATION PARTS (check all that apply) | | | | | |
| <input checked="" type="checkbox"/> Specification Number of Pages <u>91</u> | | <input type="checkbox"/> CD(s), Number _____ | | | |
| <input type="checkbox"/> Drawing(s) Number of Sheets _____ | | <input checked="" type="checkbox"/> Other (specify) <u>17 Claims on 17 pgs;</u> <u>Abstract on 1 page</u> | | | |
| <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76 | | | | | |
| METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT | | | | | |
| <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. | | | | FILING FEE Amount (\$) <div style="border: 1px solid black; padding: 10px; display: inline-block; width: 80px; text-align: center;">160.00</div> | |
| <input type="checkbox"/> A check or money order is enclosed to cover the filing fees. | | | | | |
| <input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <u>23-0455</u> | | | | | |
| <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. | | | | | |
| The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government. | | | | | |
| <input checked="" type="checkbox"/> No. | | | | | |
| <input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____ | | | | | |

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME J. Michael Dixon

TELEPHONE 734-622-1705

[Page 1 of 2]

Date November 23, 2004

REGISTRATION NO. 32,410

(if appropriate)

Docket Number: PC32216L2

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): Richard John Sciotti et al

Docket No.

PC32216L2

Serial No.

Filing Date

Examiner

Group Art

23-Nov-2004

Invention:


ANTIBACTERIAL AGENTS

I hereby certify that this PROVISIONAL APPLICATION*(Identify type of correspondence)*

Is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under
37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on November 23, 2004*(Date)*

Diane L. Hetzler

(Typed or Printed Name of Person Mailing Correspondence)*(Signature of Person Mailing Correspondence)*

EU807929945US

*("Express Mail" Mailing Label Number)***Note: Each paper must have its own certificate of mailing**

-1-

ANTIBACTERIAL AGENTS

FIELD OF THE INVENTION

The invention relates to compounds which exhibit antibacterial activity,
5 methods for their preparation, as well as pharmaceutically acceptable
compositions comprising such compounds.

BACKGROUND OF THE INVENTION

Antibacterial resistance is a global clinical and public health problem that
10 has emerged with alarming rapidity in recent years and undoubtedly will increase
in the near future. Resistance is a problem in the community as well as in health
care settings, where transmission of bacteria is greatly amplified. Because
multiple drug resistance is a growing problem, physicians are now confronted
with infections for which there is no effective therapy. The morbidity, mortality,
15 and financial costs of such infections pose an increasing burden for health care
systems worldwide. Strategies to address these issues emphasize enhanced
surveillance of drug resistance, increased monitoring and improved usage of
antimicrobial drugs, professional and public education, development of new
drugs, and assessment of alternative therapeutic modalities.


20

As a result, alternative and improved agents are needed for the treatment
of bacterial infections, particularly for the treatment of infections caused by
resistant strains of bacteria, e.g., penicillin-resistant, methicillin-resistant,
ciprofloxacin-resistant, and/or vancomycin-resistant strains.

25

SUMMARY OF THE INVENTION

These and other needs are met by the present invention, which is directed
to a compound of formula I





I

or a pharmaceutically acceptable salt thereof, wherein:

X_1 is CH_2 , NH , or O ;

5 X_2 is absent, or

is $(CH_2)_{x'}$, NH , O , , or , wherein "wavy" are points of attachment, or

is a tether 2, 3 or 4 atoms in length, selected from

10 $\sim CH_2-O\sim$, $\sim CH_2-CH_2-O\sim$, $\sim CH_2-CH_2-N\sim$
 $\sim O-CH_2-CH_2-O\sim$, $\sim O-CH_2-CH_2-N\sim$
 $\sim N-CH_2-CH_2-N\sim$ wherein R is H or (C_1-C_6) alkyl, and
 wherein "wavy" are points of attachment and x' is an integer selected
 from 1, 2, or 3;

15 Y is N , $C-H$, $C-F$, or $C-OMe$;

R_1 is H or halo;

R_2 is (C_3-C_6) cycloalkyl,

$(CH_2)_x$ -aryl,

$(CH_2)_x$ -heterocyclo, or

20 $(CH_2)_x$ -heteroaryl,

wherein x is 0, 1, or 2;

R_3 is H ,

(C_1-C_6) alkyl,

(C_3-C_6) cycloalkyl,

25 aryl,


heterocyclo,

heteroaryl,




$C(O)NR_aR_b$,

$C(O)R_a$,


30 CO_2R_a ,



5



, wherein "wavy" indicates the point of attachment,



, wherein "wavy" indicates the point of attachment,

and wherein

10

R_a is H,

(C_1 - C_6)alkyl,

(C_3 - C_6)cycloalkyl,

(CH_2) $_y$ -aryl,

15

(CH_2) $_y$ -heterocyclo, or

(CH_2) $_y$ -heteroaryl,

wherein y is 0, 1, or 2;

R_b is H,

20

(C_1 - C_6)alkyl,

(C_3 - C_6)cycloalkyl,

aryl,

heterocyclo, or

heteroaryl;

25

R_c is H,

(C_1 - C_6)alkyl,

(C_3 - C_6)cycloalkyl,

aryl,

30

heterocyclo, or

heteroaryl; and

R₄ is (C₁-C₆)alkyl, (C₁-C₆)alkyl-O-(C₁-C₆)alkyl, cyclopropyl, CH₂-cyclopropyl, or cyclobutyl.

5

The compounds of Formula I exhibit antibacterial activity. They may be used to treat bacterial infections in mammals, especially humans. The compounds may also be used for veterinary applications, such as treating infections in livestock and companion animals.

10

The compounds exhibit activity against selected strains of Gram-positive bacteria, Gram-negative bacteria, and anaerobic bacteria. They may be used to treat common infections such as otitis media, sinusitis, pharyngitis/tonsillitis, bronchitis, urinary tract infections, skin infections, pneumonia, septicemia, etc. In order to simplify administration, the compounds will typically be admixed with at least one excipient and formulated into pharmaceutical dosage forms. Examples of such dosage forms include tablets, capsules, solutions/suspensions for injection, and solutions/suspensions for oral ingestion.

15

20 Examples of Compounds encompassed by Formula I, in which Y is C-H include:

a) 3-[2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-5-yl]-[1,2,4]oxadiazole-5-carboxylic acid methylamide;

25

b) 1-{5-[5-(2-Dimethylamino-ethyl)-[1,2,4]oxadiazol-3-yl]-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl}-3-ethyl-urea;

30

c) 1-Ethyl-3-[5-(5-methoxy-[1,2,4]oxadiazol-3-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;

- d) 1-Ethyl-3-[5-(3-methoxy-[1,2,4]oxadiazol-5-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- e) 1-Ethyl-3-[5-(3-methylamino-[1,2,4]oxadiazol-5-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- 5 f) 1-Ethyl-3-{5-[5-(2-hydroxy-ethyl)-[1,3,4]oxadiazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl}-urea;
- 10 g) 1-Ethyl-3-[5-(5-methyl-[1,3,4]oxadiazol-2-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- h) 1-{5-[5-(2-Dimethylamino-ethyl)-[1,3,4]oxadiazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl}-3-ethyl-urea;
- 15 i) 1-Ethyl-3-[5-(5-methyl-[1,2,4]oxadiazol-3-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- j) 1-Ethyl-3-[5-(5-methyl-[1,3,4]thiadiazol-2-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- 20 k) 1-Ethyl-3-{5-[5-(2-hydroxy-ethyl)-[1,3,4]thiadiazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl}-urea;
- 25 l) 1-{5-[5-(2-Dimethylamino-ethyl)-[1,3,4]thiadiazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl}-3-ethyl-urea;
- m) 2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridine-5-carboxylic acid methyl ester;
- 30 n) 2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridine-5-carboxylic acid ethylamide;

- o) 1-[5-(2-Dimethylamino-acetyl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- 5 p) 1-Ethyl-3-(7-pyridin-3-yl-5-trifluoromethoxymethyl-imidazo[1,2-a]pyridin-2-yl)-urea;
- q) 1-Ethyl-3-(5-propionyl-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 10 r) 1-Ethyl-3-[5-(1-methylimino-propyl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- s) 1-(5-Cyclopropanecarbonyl-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-3-ethyl-urea;
- 15 t) 1-[5-(Cyclopropyl-methoxyimino-methyl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-3-methyl-urea;
- u) 1-[5-Cyclopropanecarbonyl-7-(2-oxo-1,2-dihydro-pyridin-4-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- 20 v) 1-Ethyl-3-[7-(2-oxo-1,2-dihydro-pyridin-4-yl)-5-propionyl-imidazo[1,2-a]pyridin-2-yl]-urea;
- w) 1-Ethyl-3-[5-(2-methanesulfonyl-ethyl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- 25 x) 1-Ethyl-3-[5-(5-methyl-4H-[1,2,4]triazol-3-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- 30

- y) 1-Ethyl-3-[5-(1-methyl-1H-pyrazol-4-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- z) 1-[5-(2-Dimethylamino-ethoxy)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- 5
- aa) 1-Ethyl-3-[7-pyridin-3-yl-5-(2-[1,2,4]triazol-1-yl-ethoxy)-imidazo[1,2-a]pyridin-2-yl]-urea;
- 10
- bb) 1-{5-[4-(2-Dimethylamino-ethyl)-thiazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl}-3-ethyl-urea;
- cc) N-Methyl-2-[2-(3-methyl-ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-5-yloxy]-acetamide;
- 15
- dd) 1-Ethyl-3-[5-(6-hydroxy-pyridin-3-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- ee) 1-{5-[4-(2-Dimethylamino-ethyl)-oxazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl}-3-ethyl-urea;
- 20
- ff) 1-[5-(2-Dimethylamino-ethoxy)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- gg) 1-Ethyl-3-[5-(2-pyrazol-1-yl-ethyl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- 25
- hh) 2-[2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-5-yl]-thiazole-4-carboxylic acid amide;
- 30
- ii) 1-Ethyl-3-[5-(2-oxo-2-pyridin-2-yl-ethyl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;

jj) 1-Ethyl-3-[5-(2-oxazol-2-yl-ethyl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;

5 kk) 1-Ethyl-3-[5-(2-methylamino-pyrimidin-5-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;

ll) 1-(5-Cyclopropyl-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-3-ethyl-urea;
and

10

mm) N-{2-[2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-5-yl]-ethyl}-acetamide.

Examples of compounds encompassed by Formula I, in which Y is N
15 include:

a) 3-[2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-5-yl]-[1,2,4]oxadiazole-5-carboxylic acid methylamide

20 b) 1-{5-[5-(2-Dimethylamino-ethyl)-[1,2,4]oxadiazol-3-yl]-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl}-3-ethyl-urea;

c) 1-Ethyl-3-[5-(5-methoxy-[1,2,4]oxadiazol-3-yl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;

25

d) 1-Ethyl-3-[5-(3-methoxy-[1,2,4]oxadiazol-5-yl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;

e) 1-Ethyl-3-[5-(3-methylamino-[1,2,4]oxadiazol-5-yl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
30

- f) 1-Ethyl-3-{5-[5-(2-hydroxy-ethyl)-[1,3,4]oxadiazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl}-urea;
- g) 1-Ethyl-3-[5-(5-methyl-[1,3,4]oxadiazol-2-yl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- h) 1-{5-[5-(2-Dimethylamino-ethyl)-[1,3,4]oxadiazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl}-3-ethyl-urea;
- i) 1-Ethyl-3-[5-(5-methyl-[1,2,4]oxadiazol-3-yl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- j) 1-Ethyl-3-[5-(5-methyl-[1,3,4]thiadiazol-2-yl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- k) 1-Ethyl-3-{5-[5-(2-hydroxy-ethyl)-[1,3,4]thiadiazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl}-urea;
- m) 1-{5-[5-(2-Dimethylamino-ethyl)-[1,3,4]thiadiazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl}-3-ethyl-urea;
- n) 2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidine-5-carboxylic acid methyl ester;
- o) 2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidine-5-carboxylic acid ethylamide;
- p) 1-[5-(2-Dimethylamino-acetyl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-3-ethyl-urea;
- q) 1-Ethyl-3-(7-pyridin-3-yl-5-trifluoromethoxymethyl-imidazo[1,2-c]pyrimidin-2-yl)-urea;

- r) 1-Ethyl-3-(5-propionyl-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl)-urea;
- s) 1-Ethyl-3-[5-(1-methoxyimino-propyl)-7-pyridin-3-yl-imidazo[1,2-
5 c]pyrimidin-2-yl]-urea;
- t) 1-(5-Cyclopropanecarbonyl-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl)-
3-ethyl-urea;
- 10 u) 1-[5-(Cyclopropyl-methoxyimino-methyl)-7-pyridin-3-yl-imidazo[1,2-
c]pyrimidin-2-yl]-3-ethyl-urea;
- v) 1-[5-Cyclopropanecarbonyl-7-(2-oxo-1,2-dihydro-pyridin-4-yl)-
imidazo[1,2-c]pyrimidin-2-yl]-3-ethyl-urea;
- 15 x) 1-Ethyl-3-[7-(2-oxo-1,2-dihydro-pyridin-4-yl)-5-propionyl-imidazo[1,2-
c]pyrimidin-2-yl]-urea;
- y) 1-Ethyl-3-[5-(2-methanesulfonyl-ethyl)-7-pyridin-3-yl-imidazo[1,2-
20 c]pyrimidin-2-yl]-urea;
- z) 1-Ethyl-3-[5-(5-methyl-4H-[1,2,4]triazol-3-yl)-7-pyridin-3-yl-
imidazo[1,2-c]pyrimidin-2-yl]-urea;
- 25 aa) 1-Ethyl-3-[5-(1-methyl-1H-pyrazol-4-yl)-7-pyridin-3-yl-imidazo[1,2-
c]pyrimidin-2-yl]-urea;
- bb) 1-[5-(2-Dimethylamino-ethoxy)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-
2-yl]-3-ethyl-urea;
- 30 cc) 1-Ethyl-3-[7-pyridin-3-yl-5-(2-[1,2,4]triazol-1-yl-ethoxy)-imidazo[1,2-
c]pyrimidin-2-yl]-urea;

dd) 1-{5-[4-(2-Dimethylamino-ethyl)-thiazol-2-yl]-7-pyridin-3-yl-
imidazo[1,2-c]pyrimidin-2-yl}-3-ethyl-urea;

5 ee) N-Methyl-2-[2-(3-methyl-ureido)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-
5-yloxy]-acetamide;

ff) 1-Ethyl-3-[5-(6-hydroxy-pyridin-3-yl)-7-pyridin-3-yl-imidazo[1,2-
c]pyrimidin-2-yl]-urea;

10

gg) 1-{5-[4-(2-Dimethylamino-ethyl)-oxazol-2-yl]-7-pyridin-3-yl-
imidazo[1,2-c]pyrimidin-2-yl}-3-ethyl-urea;

hh) 1-[5-(2-Dimethylamino-ethoxy)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-
15 2-yl]-3-ethyl-urea;

ii) 1-Ethyl-3-[5-(2-pyrazol-1-yl-ethyl)-7-pyridin-3-yl-imidazo[1,2-
c]pyrimidin-2-yl]-urea;

20 jj) 2-[2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-5-yl]-
thiazole-4-carboxylic acid amide;

kk) 1-Ethyl-3-[5-(2-oxo-2-pyridin-2-yl-ethyl)-7-pyridin-3-yl-imidazo[1,2-
c]pyrimidin-2-yl]-urea;

25

ll) 1-Ethyl-3-[5-(2-oxazol-2-yl-ethyl)-7-pyridin-3-yl-imidazo[1,2-
c]pyrimidin-2-yl]-urea;

mm) 1-Ethyl-3-[5-(2-methylamino-pyrimidin-5-yl)-7-pyridin-3-yl-imidazo
30 [1,2-c]pyrimidin-2-yl]-urea;


nn) 1-(5-Cyclopropyl-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl)-3-ethyl-
urea; and

oo) N-{2-[2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-5-yl]-
5 ethyl}-acetamide.


A more specific embodiment of the invention is directed to those
compounds of Formula I in which:

- a) Y is CH and R₁, R₂, R₃, R₄, X₁, and X₂ are as above;
- 10 b) Y is N and R₁, R₂, R₃, R₄, X₁, and X₂ are as above;
- c) Y is CH, X₂ is absent, and X₁ is NH;
- d) Y is N, X₂ is absent, and X₁ is NH;
- e) Y is N, R₂ is heteroaryl, X₂ is absent, and X₁ is NH;
- f) Y is CH, R₂ is heteroaryl, X₂ is absent, and X₁ is NH;
- 15 g) Y is N, R₂ and R₃ are each heteroaryl, X₂ is absent, and X₁ is NH;
- h) Y is CH, R₂ and R₃ are each heteroaryl, X₂ is absent, and X₁ is NH;
- i) Y is N, R₂ is heteroaryl, X₂ is absent, R₃ is represented by CO₂R_a,
COR_a or C(O)NR_aR_b and X₁ is NH;
- j) Y is CH, R₂ is heteroaryl, X₂ is absent, R₃ is represented by CO₂R_a,
20 COR_a or C(O)NR_aR_b and X₁ is NH;
- k) Y is N, R₂ is heteroaryl, X₂ is absent, R₃ is H, and X₁ is NH;
- l) Y is CH, R₂ is heteroaryl, X₂ is absent, R₃ is H, and X₁ is NH
- m) Y is N, R₂ is heteroaryl, X₂ is absent, R₃ is H, X₁ is NH and R₄ is
ethyl, isopropyl, trifluoroethyl, or cyclopropyl;
- 25 n) Y is CH, R₂ is heteroaryl, X₂ is absent, R₃ is H, X₁ is NH and, and R₄
is ethyl, cyclobutyl, isopropyl or trifluoroethyl; or;
- o) Y is N, R₂ is pyridinyl or pyrimidinyl, X₂ is absent, R₃ is H, X₁ is NH
and R₄ is ethyl, isopropyl, trifluoroethyl, or cyclopropyl.
- p) Y is CH, R₂ is pyridinyl or pyrimidinyl, X₂ is absent, R₃ is H, X₁ is
30 NH and R₄ is ethyl, isopropyl, trifluoroethyl, or cyclopropyl.


Additional compounds encompassed by Formula I include:



(7-Pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-carbamic acid ethyl ester;




5 1-Ethyl-3-(7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea;




[7-(2-Dimethylamino-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-carbamic acid ethyl ester; .


10




1-[7-(2-Dimethylamino-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;




15 1-Ethyl-3-[7-(6-methoxy-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;




[7-(6-Methoxy-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-carbamic acid ethyl ester; or



5 1-Ethyl-3-[7-(2-methoxy-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-urea.




(7-Pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl)-carbamic acid ethyl ester;




10


1-Ethyl-3-(7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl)-urea;




15 [7-(2-Dimethylamino-pyrimidin-5-yl)-imidazo[1,2-c]pyrimidin-2-yl]-carbamic acid ethyl ester;



1-[7-(2-Dimethylamino-pyrimidin-5-yl)-imidazo[1,2-c]pyrimidin-2-yl]-3-ethyl-urea;




1-Ethyl-3-[7-(6-methoxy-pyridin-3-yl)-imidazo[1,2-c]pyrimidin-2-yl]-urea;



5

[7-(6-Methoxy-pyridin-3-yl)-imidazo[1,2-c]pyrimidin-2-yl]-carbamic acid ethyl ester; or




10 1-Ethyl-3-[7-(2-methoxy-pyrimidin-5-yl)-imidazo[1,2-c]pyrimidin-2-yl]-urea.

DETAILED DESCRIPTION OF THE INVENTION


15 Reference will now be made in detail to compositions or embodiments and methods of the invention.

The term “(C₁-C₆)alkyl” as used herein refers to a straight or branched hydrocarbon from 1 to 6 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, *tert*-butyl, n-pentyl, n-hexyl, and
20 the like. The (C₁-C₆)alkyl group optionally can be substituted with one or more of the substituents selected from cycloalkyl, heterocycloalkyl, aryl, heteroaryl, (C₁-C₆)alkoxy, (C₁-C₆)thioalkoxy, halo, oxo, thio, cyano, haloalkyl, haloalkoxy,

-OH, -NO₂, -NH₂, aminoalkyl, -CO₂H, -CO₂(C₁-C₆)alkyl, -CO(C₁-C₆)alkyl, -



The term "(C₁-C₃)alkyl" as used herein refers to a straight or branched
 5 hydrocarbon of from 1 to 3 carbon atoms and includes, for example, methyl, ethyl,
 n-propyl, isopropyl, and the like. The (C₁-C₃)alkyl group optionally can be
 substituted with one or more of the substituents selected from cycloalkyl,
 heterocycloalkyl, aryl, heteroaryl, (C₁-C₆)alkoxy, (C₁-C₆)thioalkoxy, halo, oxo,
 thio, -OH, cyano, haloalkyl, haloalkoxy, -NO₂, -NH₂, aminoalkyl, -CO₂H, -

10 CO₂(C₁-C₆)alkyl, -CO(C₁-C₆)alkyl, -C(O)N(C₁-C₆)alkyl or .

The term "haloalkyl" refers to a branched or straight chained alkyl group
 containing from 1 to 6 carbon atoms, in which at least one hydrogen atom is
 replaced with a halogen (i.e. C₁-C₆ haloalkyl). Examples of suitable haloalkyl's
 15 include chloromethyl, difluoromethyl, trifluoromethyl, 1-fluoro-2-chloro-ethyl, 5-
 fluoro-hexyl, 3-difluoro-isopropyl, 3-chloro-isobutyl, etc.

The term "haloalkoxy" refers to a branched or straight chained
 alkoxy group containing from 1 to 6 carbon atoms, in which at least one hydrogen
 20 atom is replaced with a halogen (i.e. C₁-C₆ haloalkoxy). Examples of suitable
 haloalkoxy's include chloromethoxy, difluoromethoxy, trifluoromethoxy, 1-
 fluoro-2-chloro-ethoxy, 5-fluoro-hexoxy, 3-difluoro-isopropoxy, 3-chloro-
 isobutoxy, etc.

25 The term "C₁-C₆ alkoxy" refers to a straight or branched chain alkoxy
 group containing from 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propoxy,
 isopropoxy, n-butoxy, isobutoxy, pentoxy, etc.

The term "C₁-C₆ thioalkoxy" refers to a straight or branched chain thioalkoxy group containing from 1 to 6 carbon atoms, such as thiomethoxy, thioethoxy, n-thiopropoxy, isothiopropoxy, etc.

5 The term "amino" refers to -NH₂.

The term "aminoalkyl" refers to an amino moiety substituted with one or two C₁-C₆ alkyl groups. These alkyl groups may be the same or different. Examples of such aminoalkyl groups include aminomethyl, dimethylamino,
10 aminomethylethyl, aminomethylpropyl, etc.

The term "(C₃-C₆)cycloalkyl" means a hydrocarbon ring containing from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. Where possible, the cycloalkyl group may contain double bonds, for
15 example, 3-cyclohexen-1-yl. The cycloalkyl ring may be unsubstituted or optionally may be substituted by one or more substituents selected from (C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)thioalkoxy, hydroxy, thiol, halo, formyl, carboxyl, amino, aminoalkyl, -CO₂(C₁-C₆)alkyl, -CO(C₁-C₆)alkyl, -C(O)N(C₁-C₆)alkyl, aryl, heteroaryl, wherein alkyl, aryl, and heteroaryl are as defined herein, or as
20 indicated above for alkyl. Examples of substituted cycloalkyl groups include fluorocyclopropyl. Any reference in this application to a cycloalkyl group should be construed as referring to a "(C₃-C₆)cycloalkyl

25 The term "halo" includes chlorine, fluorine, bromine, and iodine.

The term "aryl" means a cyclic or polycyclic aromatic ring having from 5 to 12 carbon atoms, and may be unsubstituted or optionally may be substituted with one or more of the substituent groups recited above for alkyl groups. Examples include, but are not limited to phenyl, 2-chlorophenyl, 3-chlorophenyl,
30 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-chloro-3-methylphenyl, 2-chloro-4-methylphenyl, 2-chloro-5-methylphenyl, 3-chloro-2-methylphenyl, 3-

chloro-4-methylphenyl, 4-chloro-2-methylphenyl, 4-chloro-3-methylphenyl, 5-chloro-2-methylphenyl, 2,3-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2,3-dimethylphenyl, 3,4-dimethylphenyl, naphthyl, 4-thionaphthyl, tetralinyl, benzonaphthenyl, and 4'-bromobiphenyl.

5

The term "heteroaryl" means an aromatic cyclic or polycyclic ring system having from 1 to 4 heteroatoms selected from N, O, and S, and may be unsubstituted or optionally may be substituted with one or more of the substituent groups recited above for alkyl groups.. Typical heteroaryl groups include 1, 2, 4-oxadiazolyl, 1, 3, 4-oxadiazolyl, 1, 2, 4-thiadiazolyl, 1, 3, 4-thiadiazolyl, 2- or 3-thienyl, 2- or 3-furanyl, 2- or 3-pyrrolyl, 2-, 4-, or 5-imidazolyl, 3-, 4-, or 5-pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isoxazolyl, 3- or 5-1,2,4-triazolyl, 4- or 5-1,2,3-triazolyl, tetrazolyl, 2-, 3-, or 4-pyridinyl, 3-, 4-, or 5-pyridazinyl, 2-pyrazinyl, 2-, 4-, or 5-pyrimidinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 5-, 6-, or 7-benzothiazolyl. The heteroaryl groups may be unsubstituted or substituted by 1 to 3 substituents(if chemically permissible) selected from those described above for alkyl, for example, cyanothienyl and formylpyrrolyl. Preferred aromatic fused heterocyclic rings of from 8 to 10 atoms include but are not limited to 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl-, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 5-, 6-, or 7-benzothiazolyl. Heteroaryl also includes 2- and 3- aminomethylfuran, 2- and 3- aminomethylthiophene and the like.

10
15
20
25

The terms "heterocyclic , heterocycloalkyl and heterocyclo" are synonyms and each means a saturated or unsaturated (but not aromatic) monocyclic, fused, bridged, or spiro bicyclic heterocyclic ring systems and may be unsubstituted or optionally may be substituted with one or more of the substituent groups recited above for alkyl groups. Monocyclic heterocyclic rings contain from about 3 to 12

30

ring atoms, with from 1 to 5 heteroatoms selected from N, O, and S, and preferably from 3 to 7 member atoms, in the ring. Bicyclic heterocyclics contain from about 5 to about 17 ring atoms, preferably from 5 to 12 ring atoms. Bicyclic heterocyclic rings may be fused, spiro, or bridged ring systems. Examples of

5 heterocyclic groups include cyclic ethers (oxiranes) such as ethyleneoxide, tetrahydrofuran, dioxane, and substituted cyclic ethers, wherein the substituents are those described above for the alkyl and cycloalkyl groups. Typical substituted cyclic ethers include propyleneoxide, phenyloxirane (styrene oxide), cis-2-butene-oxide (2,3-dimethyloxirane), 3-chlorotetrahydrofuran, 2,6-dimethyl-1,4-dioxane,

10 and the like. Heterocycles containing nitrogen are groups such as pyrrolidine, piperidine, piperazine, tetrahydrotriazine, tetrahydropyrazole, and substituted groups such as 3-aminopyrrolidine, 4-methylpiperazin-1-yl, and the like. Typical sulfur containing heterocycles include tetrahydrothiophene, dihydro-1,3-dithiol-2-yl, and hexahydrothiophen-4-yl and substituted groups such as aminomethyl

15 thiophene. Other commonly employed heterocycles include dihydro-oxathiol-4-yl, dihydro-1*H*-isindole, tetrahydro-oxazolyl, tetrahydro-oxadiazolyl, tetrahydrodioxazolyl, tetrahydrooxathiazolyl, hexahydrotriazinyl, tetrahydro-oxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl.

20 For heterocycles containing sulfur, the oxidized sulfur heterocycles containing SO or SO₂ groups are also included. Examples include the sulfoxide and sulfone forms of tetrahydrothiophene.

R₂ and R₃ may each be represented by an aryl or heteroaryl moiety. For

25 any compound substituted at either position with such a moiety, it is relevant to point that these aryl and heteroaryl's may be substituted. Permissible substituents include other heteroaryl, aryl, arylalkyl, heteroaryl alkyl, aryl alkoxy, heteroaryl alkoxy, aryl thioalkoxy, and heteroaryl thioalkoxy.

30 When a bond is represented by a symbol such as "-----" this is meant to represent that the bond may be absent or present provided that the resultant compound is stable and of satisfactory valency.

When a bond is represented by a line such as "~~~~" this is meant to represent that the bond is the point of attachment between two molecular subunits.

The term "patient" and "subject" are synonyms and mean all mammals, including humans. Other examples of patients include cows, dogs, cats, goats, sheep, pigs, and rabbits.

A "therapeutically effective amount" is an amount of a compound of the present invention that, when administered to a patient, provides the desired effect; i.e., lessening in the severity of the symptoms associated with a bacterial infection.

It will be appreciated by those skilled in the art that compounds of the invention having one or more chiral centers may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, geometric, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare such forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase).

Certain compounds of Formula I are also useful as intermediates for preparing other compounds of Formula I.

Some of the compounds of Formula I are capable of further forming pharmaceutically acceptable acid-addition and/or base salts. All of these forms are within the scope of the present invention. Thus, pharmaceutically acceptable acid addition salts of the compounds of Formula I include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids,

phenyl-substituted alkanolic acids, hydroxy alkanolic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinates suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge S.M. et al., "Pharmaceutical Salts," *Journal of Pharmaceutical Science*, 1977;66:1-19).

The acid addition salt of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge S.M., supra., 1977).

The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner.

Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.

A "prodrug" is an inactive derivative of a drug molecule that requires a chemical or an enzymatic biotransformation in order to release the active parent drug in the body.

Specific and preferred values for the compounds of the present invention are listed below for radicals, substituents, and ranges are for illustration purposes only, and they do not exclude other defined values or other values within defined ranges for the radicals and substituents.

Preparation of Invention Compounds

10

Strategies for the preparation of invention compounds are depicted in Schemes I and II, and more specifically in Schemes 1-7. The numbering conventions for the "R" and "X" substituents, R₁, R₂, X₂, R₃, X₁, and R₄ are as provided for in the compounds of formula I.


15

Thus, as depicted retrosynthetically in Scheme I, the fused bicyclic core that characterizes the compounds of Formula I can be constructed via reaction of an appropriately substituted pyridinyl (Y= C-H, C-F, C-OMe) or pyrimidinyl (Y= N) derivative, as depicted by structure (1) with (2-chloro-acetyl)-carbamic acid ethyl ester, *N*-(chloroacetyl)-*N'*-ethylurea or an equivalent, in the presence of an

20


amine base. The requisite appropriately substituted pyridinyl (Y= C-H, C-F, C-OMe) or pyrimidinyl (Y= N) derivatives 1 can be prepared by coupling compound 2, with compound 3, or the like.

Scheme I




- 5 Schemes 1 and 2 exemplify an approach to compounds wherein R_2 is aryl, heteroaryl, Y is N, C-H, C-F, or C-OMe, and X_1 is NH or O. Thus, in Scheme 1, palladium catalyzed coupling of 4-bromo-pyridin-2-ylamine (1) with borane (2) provides [3,4']bipyridinyl-2'-ylamine (3). Reaction of compound 3 with (2-chloro-acetyl)-carbamic acid ethyl ester or 1-(2-chloro-acetyl)-3-ethyl-urea in the
- 10 presence of an amine base such as lutidine (although other amine bases known to the practitioner could also be used) provides the invention compounds.

Scheme 1



- 15 Similarly in Scheme 2, palladium-catalyzed coupling of compound (1) with borane (4) provides [5-(2-amino-pyridin-4-yl)-pyrimidin-2-yl]-dimethylamine (5). In a similar fashion as disclosed in Scheme 1, compound 5 can be converted to the invention compounds.


Scheme 2



Schemes 3 and 4 provide additional variants of the approach presented in


5 Scheme I.

Scheme 3



10

Scheme 4




Scheme II discloses a retrosynthetic approach to variously substituted compounds of formula I wherein the combination of X_2R_3 is other than H. Initially compound 1, in which the combination of X_2R_3 is lower alkyl ester, heteroaryl, amino, or the like, is subjected to a coupling reaction with compound 2, similar to that disclosed in Scheme 1 above, generating compound 3. Compound 3 is then cyclized to compound 4 using bromo-pyruvate. Compound 4

can be rearranged to compound I, using the Lossen, Hofmann or Curtius rearrangements, which are described in Organic Syntheses Based on Named and Unnamed Reactions, Pergamon, Vol. 11, A. Hassner et al. (1994).

Depending upon the final product the reaction may be complete or subsequent functionalization reactions may be carried out as is known in the art to achieve the desired substituent at the X_2R_3 position. By way of illustrative example, when the invention compound X_2 is absent and R_3 is a methyl ester, methods for converting carboxylic esters into oxadiazoles or thiadiazoles are described in Synthesis 2003, 6, 899-905; Journal of Medicinal Chemistry 1991, 34(1), 140-151; Indian Journal of Heterocyclic Chemistry 2002, 12(3), 289-290. Likewise, the conversion of carboxylic esters into oxazoles is described in Synthesis 1998, (9), 1298-1304; Journal of Organic Chemistry 1989, 54(2), 431-434. Methods for preparing triazoles are described in Journal of the Chemical Society, Dalton Transactions 2002, (8), 1740-1746.

15


Scheme II



20

Scheme 5 provides an approach to invention compounds wherein X_2 is O, R_2 is aryl or heteroaryl (i.e. HetAr), and R_3 is as defined herein.


5



A variant of the Scheme 5 approach is provided in Scheme 6, wherein the X_2-R_3 (e.g., OR) is introduced at the beginning, rather than the end of the

10


synthesis.



15

An approach to the preparation of compounds of formula I wherein Y is N is provided in Scheme 7 commencing with intermediates A or B, which may be prepared as disclosed in the art.

Scheme 7



5

Pharmaceutical Formulations

The present invention also provides pharmaceutical compositions which comprise a bioactive invention compound, a salt thereof or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier. The compositions include those in a form adapted for oral, topical or parenteral use and can be used for the treatment of bacterial infection in mammals including humans.

10

Compounds of the invention can be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other

bioactive agents such as antibiotics. Such methods are known in the art and are not described in detail herein.

The composition can be formulated for administration by any route known in the art, such as subdermal, inhalation, oral, topical, parenteral, etc. The
5 compositions may be in any form known in the art, including but not limited to tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.

The topical formulations of the present invention can be presented as, for
10 instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams. The formulations may also contain compatible
15 conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present, for example, from about 1% up to about 98% of the formulation. For example, they may form up to about 80% of the formulation.

Tablets and capsules for oral administration may be in unit dose
20 presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato
25 starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice.

Oral liquid preparations may be in the form of, for example, aqueous or
30 oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives, such as suspending

agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerin, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavoring or coloring agents.

For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle or other suitable solvent. In preparing solutions, the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing.

Advantageously, agents such as local anesthetics, preservatives and buffering agents etc., can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The compositions may contain, for example, from about 0.1% to about 99 by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will contain, for example, from about 5-900 mg of the active ingredient. The dosage as employed for adult human treatment will range, for example, from about 10 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of

administration. Such a dosage corresponds to about 1.5 to 500 mg/kg per day. Suitably the dosage is, for example, from about 5 to 20 mg/kg per day.

Biological Activity

5

In one embodiment, the invention provides methods of treating or preventing a bacterial infection in a subject, such as a human or other animal subject, comprising administering an effective amount of an invention compound as disclosed herein to the subject. In one embodiment, the compound is
10 administered in a pharmaceutically acceptable form optionally in a pharmaceutically acceptable carrier. As used herein, an "infectious disorder" is any disorder characterized by the presence of a microbial infection, such as bacterial infections. Such infectious disorders include, for example central nervous system infections, external ear infections, infections of the middle ear,
15 such as acute otitis media, infections of the cranial sinuses, eye infections, infections of the oral cavity, such as infections of the teeth, gums and mucosa, upper respiratory tract infections, lower respiratory tract infections, genitourinary infections, gastrointestinal infections, gynecological infections, septicemia, bone and joint infections, skin and skin structure infections, bacterial endocarditis,
20 burns, antibacterial prophylaxis of surgery, and antibacterial prophylaxis in immunosuppressed patients, such as patients receiving cancer chemotherapy, or organ transplant patients. The compounds and compositions comprising the compounds can be administered by routes such as topically, locally or systemically. Systemic application includes any method of introducing the
25 compound into the tissues of the body, e.g., intrathecal, epidural, intramuscular, transdermal, intravenous, intraperitoneal, subcutaneous, sublingual, rectal, and oral administration. The specific dosage of antimicrobial to be administered, as well as the duration of treatment, may be adjusted as needed and will be determined by the subjects physician.

30

The compounds of the invention may be used for the treatment or prevention of infectious disorders caused by a variety of bacterial organisms.


Examples include Gram positive and Gram negative aerobic and anaerobic bacteria, including Staphylococci, for example *S. aureus*; Enterococci, for example *E. faecalis*; Streptococci, for example *S. pneumoniae*; Haemophilus, for example *H. influenza*; Moraxella, for example *M. catarrhalis*; and Escherichia, for example *E. coli*. Other examples include Mycobacteria, for example *M. tuberculosis*; intercellular microbes, for example Chlamydia and Rickettsiae; and Mycoplasma, for example *M. pneumoniae*.

The ability of a compound of the invention to inhibit bacterial growth, demonstrate in vivo activity, and enhanced pharmacokinetics are demonstrated using pharmacological models that are well known to the art, for example, using models such as the tests described below.

The following examples are provided to illustrate but not limit the claimed invention.

Example 1

Preparation of (7-Pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-carbamic acid ethyl ester and 1-Ethyl-3-(7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea



Step 1: Preparation of [3,4']Bipyridinyl-2'-ylamine

2N Na_2CO_3 (20 mL, 0.04 mol) was added to a suspension of aminopyridine (1) (1.00g, 5.78 mmol) and boronic acid (2) (1.06 g, 8.67 mmol) in

toluene (60 mL) and the mixture was purged with nitrogen gas.

Bis(diphenylphosphino)ferrocenepalladium(II) chloride, dichloromethane complex [hereinafter "PdCl₂(dppf)"] (0.17 g, 0.21 mmol) was added and the mixture was refluxed under nitrogen for 1.5 hours. Ethyl acetate was added and the solution was washed with water, dried over Na₂SO₄ and adsorbed onto silica by removal of solvent *in vacuo*. The residue was chromatographed on silica, eluting with MeOH/EtOAc (1:15) to give product (3) as a powder (0.87 g, 87%). APCI-MS found: [M+H]⁺=172.

10 **Step 2: Preparation of (7-Pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-carbamic acid ethyl ester (Example 1A)**

A solution of aminopyridine (3) (0.94 g, 5.49 mmol), ethyl chloroacetylcarbamate (1.09 g, 6.58 mmol) and 2,6-lutidine (0.76 mL, 6.58 mmol) in 1,3-dimethyl-2-imidazolidinone (6 mL) was warmed under nitrogen at 110 °C for 4.5 hours. The mixture was diluted with EtOAc and washed with water (6 times), then adsorbed onto silica by removal of solvent *in vacuo*. The product was chromatographed on silica. Elution with EtOAc gave foreruns, while MeOH/EtOAc (2:23) eluted product (79 mg, 5%) as a solid, mp 248-252 °C (decomposed).

20

Step 3: Preparation of 1-Ethyl-3-(7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea (Example 1B)

A solution of aminopyridine (3) (0.73 g, 4.26 mmol), *N*-(chloroacetyl)-*N*-ethylurea (0.84 g, 5.10 mmol) and 2,6-lutidine (0.59 mL, 5.10 mmol) in 1,3-dimethyl-2-imidazolidinone (7 mL) was warmed under nitrogen at 110 °C for 5 hours. The mixture was diluted with EtOAc and washed with water (6x), then adsorbed onto silica by removal of solvent *in vacuo*. Silica gel chromatography (EtOAc gradient to MeOH/EtOAc (2:23)) provided the product (0.76 mg, 6%) as a solid, mp 290-294 °C (decomposed).


30

Examples 2-4

Using the general procedure of Example I, but substituting the relevant starting material, the following compounds were prepared:

5

2A) [7-(2-Dimethylamino-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-carbamic acid ethyl ester




10

as a solid, mp 270-280 °C (decomposed). ¹H NMR (400 MHz, DMSO-D₆)
δ ppm 10.14 (br, 1H), 8.82 (s, 2H), 8.54 (d, J=7.0 Hz, 1H), 7.82 (br s, 1H), 7.68
(d, J=1.8 Hz, 1H), 7.21 (dd, J=7.0, 1.8 Hz, 1H), 4.16 (q, J=7.1 Hz, 2H), 3.18 (s,
6H), 1.25 (t, J=7.1 Hz, 3H).

15


2B) 1-[7-(2-Dimethylamino-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea



20

as a solid, mp 259-263 °C (decomposed). ¹H NMR (400 MHz, DMSO-D₆)
δ ppm 8.84 (br s, 1H), 8.81 (s, 2H), 8.50 (d, J=7.1 Hz, 1H), 7.71 (s, 1H), 7.65 (d,
J=1.8 Hz, 1H), 7.18 (dd, J=7.1, 1.8 Hz, 1H), 6.70 (br, 1H), 3.18 (s, 6H), 3.16 (dq,
J=7.1, 5.4 Hz, 2H), 1.08 (t, J=7.1 Hz, 3H).

3A) [7-(6-Methoxy-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-carbamic acid ethyl ester




5

as a solid, mp 273-279 °C (decomposed). ¹H NMR (400 MHz, DMSO-D₆)

δ ppm 10.17 (br s, 1H), 8.62 (d, J=2.3 Hz, 1H), 8.56 (d, J=7.1 Hz, 1H), 8.14 (dd, J=8.7, 2.3 Hz, 1H), 7.86 (br s, 1H), 7.70 (br s, 1H), 7.23 (dd, J=7.1, 1.8 Hz, 1H), 6.93 (d, J=8.7 Hz, 1H), 4.16 (q, J=7.1 Hz, 2H), 3.91 (s, 3H), 1.26 (t, J=7.1 Hz,

10 3H).

3B) 1-Ethyl-3-[7-(6-methoxy-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea




15

as a solid, mp 222-225 °C (decomposed). ¹H NMR (400 MHz, DMSO-D₆)

δ ppm 8.86 (br s, 1H), 8.61 (d, J=2.3 Hz, 1H), 8.52 (d, J=7.1 Hz, 1H), 8.13 (dd, J=8.7, 2.3 Hz, 1H), 7.74 (br s, 1H), 7.67 (br s, 1H), 7.20 (dd, J=7.1, 1.8 Hz, 1H), 6.92 (d, J=8.7 Hz, 1H), 6.69 (br, 1H), 3.91 (s, 3H), 3.16 (dq, J=7.1, 5.7 Hz, 2H),

20 3.91 (s, 3H), 1.08 (t, J=7.1 Hz, 3H).

4) 1-Ethyl-3-[7-(2-methoxy-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-urea




5 as a solid, mp >300 °C. ¹H NMR (400 MHz, DMSO-D₆) δ ppm 9.05 (s, 2H), 8.90 (br, 1H), 8.57 (dd, J=7.0, 0.6 Hz, 1H), 7.80 (br s, 1H), 7.78 (s, 1H), 7.26 (dd, J=7.0, 1.8 Hz, 1H), 6.66 (br, 1H), 3.98 (s, 3H), 3.16 (dq, J=7.2, 5.5 Hz, 2H), 1.08 (t, J=7.2 Hz, 3H).

10

Example 5

Preparation of (7-Pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl)-carbamic acid ethyl esters



15

Step 1: Preparation of 6-Amino-4-chloropyrimidine (1)

4,6-Dichloropyrimidine (10.0 g, 67.1 mmol) in ammonia saturated ethanol (40 mL) was heated to 100°C in a stainless steel pressure vessel for 1.5 h.

20 Removal of the solvent *in vacuo* gave a solid which was triturated with water (270 mL) then filtered to give 6-amino-4-chloropyrimidine (1) (6.18 g, 71%) as white crystals. APCI-MS Found [M + H]⁺ = 130, 132.

Step 2: Preparation of (7-Chloro-imidazo[1,2-c]pyrimidin-2-yl)-carbamic acid ethyl ester (2)

5 A solution of 6-amino-4-chloropyrimidine (1) (0.504 g, 3.89 mmol) and *N*-chloroacetylurethane (0.770 g, 4.65 mmol) in 1,3-dimethyl-2-imidazolidinone (10 mL) was heated to 130°C under nitrogen for 3 h. *N*-Chloroacetylurethane (0.770 g, 4.65 mmol) was added and the mixture was heated to 130°C under nitrogen for a further 3.5 h. The black oily solution was poured onto ice (200 g) and the
10 aqueous solution was extracted with ethyl acetate (3 x 250 mL). The organic fractions were combined, removal of solvent *in vacuo* gave an oily solid which was triturated with ether. Filtration of the solid and washing with ether gave urethane (2) (88 mg, 9%) as a solid. APCI-MS Found $[M + H]^+ = 241, 243$.


15 **Step 3: Preparation of (7-Pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl)-carbamic acid ethyl ester**

 A mixture of (2) (0.143 g, 0.594 mmol) and 3-pyridineboronic acid (0.110 g, 0.895 mmol) in 1,4-dioxane (10 mL) and aqueous potassium carbonate (2 mol
20 L⁻¹, 2 mL) was purged with nitrogen. Bis(diphenylphosphino)ferrocenepalladium(II) chloride, dichloromethane complex (0.030 g, 0.037 mmol) was added and the mixture was refluxed under nitrogen for 16 h. The mixture was filtered through celite and the filter cake was washed with hot dioxane (2 x 50 mL). Removal of the solvent *in vacuo* gave a
25 solid which was purified by silica gel chromatography (9:1; ethyl acetate:methanol) to give substituted pyridine (3) (0.104 g) as a solid. HRMS-ET⁺ Found 283.1067. Calcd for C₁₄H₁₃N₅O₂: 283.1069.


Example 6

30


Preparation of 1-Ethyl-3-{7-[6-(2-morpholin-4-yl-ethoxy)-pyridin-3-yl]-imidazo[1,2-a]pyridin-2-yl}-urea



Scheme 1)-Preparation of Pyridyl Side Chain



5 Scheme 2: Preparation of 1-Ethyl-3-{7-[6-(2-morpholin-4-yl-ethoxy)-pyridin-2-yl]-urea} (12)



Experimental Procedure

Step 1 (synthetic scheme 1):

A solution of 4-(2-hydroxyethyl)morpholine (2.77 g, 21.1 mmol) in dry
5 tetrahydrofuran (5 mL) was added to a refluxing suspension of sodium hydride
(557 mg, 23.2 mmol) in tetrahydrofuran (50 mL). This mixture was heated at
reflux temperature for 3 h., then 2,5-dibromopyridine (1; 5.00 g, 21.1 mmol)
added as a solid (portion wise). The resulting mixture was then heated at reflux
for 15 h. After allowing the reaction mixture to cool, it was diluted with ethyl
10 acetate (200 mL), then washed with water (200 mL). The water fraction was back-
extracted with ethyl acetate (100 mL). The combined ethyl acetate fractions were
washed with water (2x200 mL), then brine (100 mL) and dried over sodium
sulfate. The drying agent was removed by filtration and the resultant liquor was
concentrated under reduced pressure. The resulting yellow oil was purified by
15 chromatography on silica gel (100% dichloromethane gradient to 10%
methanol/dichloromethane). Compound 2 was isolated as a yellow oil (yield: 5.06
g, 84%);

Step 2:

20 A solution of bromide 2 (5.00 g, 17.4 mmol) and triisopropylborate (3.93
g, 20.9 mmol) in a mixture of dry tetrahydrofuran (9 mL) and dry toluene (36 mL)
was placed under nitrogen and cooled to -78°C (acetone/dry ice). *n*-Butyllithium
(2.5 M in hexanes; 8.36 mL, 20.9 mmol) was added drop wise over 20 minutes
and the mixture was allowed to stir for 0.5 h. at -78°C . The reaction mixture was
25 then removed from the cold bath and water (50 mL) added. 2 M hydrogen
chloride (25 mL) was then added and the mixture stirred for 1 h at 23°C . After
this time further 2 M hydrogen chloride (25 mL) was added and the mixture
partitioned into ethyl acetate (100 mL). The aqueous layer was collected, then the
ethyl acetate layer extracted with further 2 M hydrogen chloride (25 mL). All
30 acidic fractions were combined, neutralized with conc. ammonia, and the resulting
oil extracted into ethyl acetate (8x50 mL). The first fraction contained both the
desired product 3 and unreacted starting material 2 by thin layer chromatography

and these were separated by chromatography on silica gel (5-10% methanol/dichloromethane). All remaining fractions contained pure boronic acid

3. All pure fractions were then combined to give compound 3 as a foam (yield: 2.56 g, 58%); ¹H NMR [400 MHz, (CD₃)₂SO] δ 8.26 (d, J = 1.3 Hz, 1 H), 8.10 (s, 2 H), 7.99 (dd, J = 8.3, 2.0 Hz, 1 H), 6.75 (d, J = 8.3 Hz, 1 H), 4.38 (t, J = 5.8 Hz, 2 H), 3.56 (t, J = 4.7 Hz, 4 H), 2.66 (t, J = 5.9 Hz, 2 H), 2.45 (t, J = 4.6 Hz, 4 H).

Step 3 (synthetic scheme 2):

2-Amino-4-bromopyridine 4 (5.00 g, 28.9 mmol) and *p*-toluenesulfonyl chloride (6.10 g, 31.8 mmol) were dissolved in dry pyridine (100 mL) and heated at 80°C for 5 h. The pyridine was removed under reduced pressure to give a solid. The solid was suspended in ethyl acetate, then collected by filtration and washed with ethyl acetate to give the tosylate 5 as a crystalline solid (yield: 7.50 g, 79%); ¹H NMR [400 MHz, (CD₃)₂SO] δ 11.6 (v br s, 1 H), 7.99 (br d, J = 5.6 Hz, 1 H), 7.78 (d, J = 8.3 Hz, 2 H), 7.37 (d, J = 7.0 Hz, 2 H), 7.27 (br s, 1 H), 7.17 (br d, J = 5.2 Hz, 1 H), 2.36 (s, 3 H).

Step 4:

Tosylate 5 (7.05 g, 21.5 mmol) was dissolved in dry dimethyl formamide (120 mL), to this was added diisopropylethylamine (3.06 g, 23.7 mmol) and iodoacetamide (4.38 g, 23.7 mmol). The mixture was stirred at 23 °C for 24 h. then concentrated under reduced pressure to provide an oil. This oil was diluted with water (300 mL) and the resulting solid collected by filtration and washed with ethyl acetate, providing the desired compound 6 (yield: 7.39 g, 89%); ¹H NMR [400 MHz, (CD₃)₂SO] δ 7.96 (d, J = 7.1 Hz, 1 H), 7.74 (s, 1 H), 7.66 (d, J = 8.2 Hz, 2 H), 7.54 (d, J = 2.1 Hz, 1 H), 7.35 (s, 1 H), 7.29 (d, J = 8.0 Hz, 2 H), 7.00 (dd, J = 7.1, 2.2 Hz, 1 H), 4.78 (s, 2 H), 2.35 (s, 3 H).

Step 5:

Compound 6 (3.18 g, 8.27 mmol) was suspended in a mixture of dichloromethane (60 mL) and trifluoroacetic anhydride (60 mL). This mixture was heated at reflux temperature for 3 h. All solvent was removed under reduced

pressure and the residue partitioned between ethyl acetate (200 mL) and sat. sodium bicarbonate (200 mL). The ethyl acetate layer was then washed with additional sodium bicarbonate (200 mL), brine (100 mL), and dried (sodium sulfate). The solvent was removed under reduced pressure to give a crude pink solid which was purified by filtration through a plug of silica gel (50% ethyl acetate/hexanes), then the resulting white solid suspended in diethyl ether and collected by filtration. Trifluoroacetamide **7** was isolated as a solid (yield: 1.57 g, 62%); ^1H NMR [400 MHz, $(\text{CD}_3)_2\text{SO}$] δ 12.49 (s, 1 H), 8.57 (d, $J = 7.2$ Hz, 1 H), 8.28 (s, 1 H), 7.84 (d, $J = 1.9$ Hz, 1 H), 7.13 (dd, $J = 7.2, 2.0$ Hz, 1 H).

Step 6:

Trifluoroacetamide **7** (607 mg, 1.97 mmol) was dissolved/suspended in a mixture of methanol (35 mL) and water (23 mL), to which was added potassium carbonate (1.36 g, 9.86 mmol). This mixture was heated at reflux for 2 h, at which point thin layer chromatography (5% methanol/dichloromethane) showed complete reaction of the starting material **7** to give a single, more polar product. The reaction was allowed to cool, diluted with water (100 mL) and extracted with ethyl acetate (4x50 mL). The combined ethyl acetate fractions were then washed with water (2x50 mL), brine (50 mL), dried (sodium sulfate) and the solvent removed under reduced pressure to afford the desired amine **8** as a solid which decomposed rapidly (to baseline overnight) and was used directly in the next step (yield: 375 mg, 97%); ^1H NMR [400 MHz, $(\text{CD}_3)_2\text{SO}$] δ 8.24 (d, $J = 7.1$ Hz, 1 H), 7.42 (d, $J = 2.0$ Hz, 1 H), 7.02 (s, 1 H), 6.85 (dd, $J = 7.0, 2.0$ Hz, 1 H), 5.27 (v br s, 2 H).

Step 7:

Amine **8** (823 mg, 4.18 mmol) was dissolved/suspended in dry tetrahydrofuran (70 mL), the reaction flushed with nitrogen, then ethyl isocyanate (1.80 g, 23.0 mmol) added. This mixture was stirred at 23 °C for 5 h., then all solvent removed under reduced pressure. The resulting crude solid was then purified by chromatography on silica gel (2% methanol/dichloromethane as eluant) to give a mixture of products **9** and **10** (yield: 777 mg, 66%). This mixture

(9:10 in a ratio of 56:44 by ^1H NMR) was used directly and subsequently separated at step 8.

Step 8:


5 A mixture of compounds **9** and **10** (777 mg, 2.76 mmol) was dissolved/suspended in dioxane (120 mL) and triethylamine (1 mL). Di-*tert*-butyldicarbonate (1.20 g, 5.51 mmol) and 4-dimethylaminopyridine (31 mg, 0.28 mmol) were added and the mixture stirred at 23 C for 3 h. All solvent was removed under reduced pressure to afford a crude solid which was purified by
10 chromatography on silica gel. The *bis*-BOC compound **11** was eluted first (50% ethyl acetate/hexanes as eluant) and discarded then the desired compound **9** was recovered (100% ethyl acetate) as a solid (296 mg,); ^1H NMR [400 MHz, $(\text{CD}_3)_2\text{SO}$] δ 8.89 (s, 1 H), 8.45 (dd, $J = 7.1, 0.5$ Hz, 1 H), 7.79 (s, 1 H), 7.63 (d, $J = 1.9$ Hz, 1 H), 6.99 (dd, $J = 7.1, 2.0$ Hz, 1 H), 6.53 (br s, 1 H), 3.14 (dq, $J = 7.2,$
15 5.6 Hz, 2 H), 1.06 (t, $J = 7.2$ Hz, 3 H).

Step 9:

Compound **9** (135 mg, 0.48 mmol) was suspended in toluene (8 mL), to which was added a solution of the boronic acid **3** (181 mg, 0.72 mmol) in ethanol
20 (2 mL). 2 M Sodium carbonate (2.0 mL) was added and the flask placed under nitrogen. The catalyst Bis(diphenylphosphino)ferrocenepalladium(II) chloride, dichloromethane complex (31 mg, 0.02 mmol) was added last and the reaction mixture heated at reflux temperature for 2 h., at which point all starting material had been consumed by thin layer chromatography (5%
25 methanol/dichloromethane). After allowing the reaction to cool, all solvents were removed under reduced pressure to give a residue which was purified by chromatography on silica gel (2% methanol/dichloromethane as eluant), affording 1-ethyl-3-{7-[6-(2-morpholin-4-yl-ethoxy)-pyridin-2-yl]-urea (**12**) as a solid after trituration with ethyl acetate (94 mg.); Anal. calcd for $\text{C}_{21}\text{H}_{26}\text{N}_6\text{O}_3$: C, 61.5; H,
30 6.4; N, 20.5. Found: C, 61.1; H, 6.3; N, 20.2.

Example 7

**Preparation of 1-Ethyl-3-(5-hydroxymethyl-7-pyridin-3-yl-imidazo[1,2-
a]pyridin-2-yl)-urea (example 7A, compound 12 in scheme), 1-Ethyl-3-(5-
5 formyl-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea (13), and 2-(3-Ethyl-
ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridine-5-carboxylic acid methyl ester
(Example 7B, compound 14 in scheme)**



Step 1:

A solution of aminopyridine (1) (0.50 g, 2.04 mmol) and p-toluenesulfonyl chloride (0.43 g, 2.24 mmol) in dry pyridine (10 mL) was warmed at 85 °C for 15 h. The solvent was removed *in vacuo* and the residue was partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. The ethyl acetate layer was washed well with water and worked up to give an oily solid, which was chromatographed on silica. Elution with ethyl acetate/petroleum ether (3:7) gave (2) as a colorless foam (0.66 g, 81%). APCI-MS Found [M+H]=401, 399.

10

Step 2:

To a solution of the ester (2) (3.71 g, 9.29 mmol) in methanol (200 mL) was added 1 N sodium hydroxide (27.0 mL, 0.027 mol) and the mixture was stirred at 23 °C for 3 h. After acidification to pH~3 with conc. hydrogen chloride the methanol was removed *in vacuo* and the residue was extracted with ethyl acetate. The extract was worked up to give the acid (3) as a solid (3.33 g, 96.5 %). APCI-MS Found [M+H]=374, 372.

20 **Step 3:**

1,1'-Carbonyldiimidazole (2.18 g, 0.013 mol) was added in portions to a solution of the acid (3) (3.33 g, 8.97 mmol) in dry tetrahydrofuran (150 mL) and the solution was stirred at 23 °C for 1 h and then poured into a vigorously stirred solution of sodium borohydride (1.02 g, 0.027 mol) in water (200 mL). After stirring at 23 °C for 30 min the mixture was acidified to pH=3 with conc. hydrogen chloride, diluted with water and extracted three times with ethyl acetate. The combined extracts were washed with 1N hydrogen chloride and worked up to give an oil, which was chromatographed on silica. Elution with ethyl acetate/petroleum ether (1:1) gave the alcohol (4) (3.17 g, 98%) as a solid. APCI-MS Found [M+H]=359, 357.

30

Step 4:

Sodium hydride (0.57 g of a 60% dispersion in mineral oil, 0.014 mol) was added in portions at 23 °C to a stirred solution of the alcohol (4) (4.22 g, 0.012 mol) in dry dimethyl formamide (60 mL). After 10 min a solution of iodoacetamide (2.68 g, 0.014 mol) in dimethyl formamide (10 mL) was added and the solution was stirred at 23 °C for 16 h. Silica gel was added and the reaction mixture was adsorbed directly onto it by concentration of the mixture to dryness *in vacuo*. The product was chromatographed on silica. Elution with ethyl acetate gave isomer (6) as a white solid (3.16 g, 63%). Elution with methanol/ethyl acetate (5:95) gave the required product (5) as a foamy solid (4.92 g-contains sodium iodide as well). This material was used directly in the next step. APCI-MS Found [M+H]=416, 414.

Step 5:

The crude product (5) from the above reaction (4.92 g) was dissolved in dichloromethane/trifluoroacetic anhydride (1:1) (40 mL) and the solution was refluxed for 2 h. After removal of the solvents *in vacuo* the residue was dissolved in methanol (50 mL), saturated aqueous sodium bicarbonate (10 mL) was added and the mixture was stirred at 23 °C for 15 min. The mixture was diluted with water and extracted with ethyl acetate. The combined extracts were concentrated *in vacuo*. Silica gel chromatography (ethyl acetate gradient to methanol/ethyl acetate (5:95)) provided the product (7) as a solid (1.44 g). APCI-MS Found [M+H]=340, 338.

Step 6:

Dihydropyran (5 mL, 0.055 mol) was added to a solution of the alcohol (7) (1.10 g, 3.25 mmol) and camphor-10-sulfonic acid (1.20 g, 5.16 mmol) in tetrahydrofuran (100 mL) and the solution was stirred at 23 °C for 2 h. Excess aqueous saturated sodium bicarbonate solution was added and the mixture was

extracted with ethyl acetate. The combined extracts were concentrated under reduced pressure to give the tetrahydropyran ether (8) as an oil (1.31 g). APCI-MS Found [M+H]=424, 422.

5 Steps 7 and 8:

A solution of the trifluoroacetamide (8) (1.60 g, 3.79 mmol) in ethanol (50 ml) and 1N sodium hydroxide (20 mL) was refluxed for 30 min. Most of the ethanol was removed *in vacuo* and the residue was diluted with water and
10 extracted with ethyl acetate. The extract was concentrated to give the crude amino compound (9) as an oily solid, which was used directly. APCI-MS Found [M+H]=328, 326. The crude amine (9) was dissolved in dry tetrahydrofuran (40 ml) and the solution was flushed with nitrogen. Ethyl isocyanate (0.61 mL, 7.82 mmol) was added and the solution was stirred at 23 °C for 2.5 h. A further 0.20
15 mL of ethyl isocyanate was added and stirring was continued for a total of 5 h. The solvent was removed *in vacuo* and the residue was adsorbed onto silica gel. Silica gel chromatography (ethyl acetate/petroleum ether gradient to ethyl acetate) provided the urea (10) as a powder (0.47 g). APCI-MS Found [M+H]=399, 397.

20 Step 9:

A suspension of pyridyl-3-boronic acid (81 mg, 0.66 mmol) in ethanol (2 mL) was added to a suspension of the bromide (10) (0.17 g, 0.43 mmol) in toluene (5 mL). After a few minutes a clear solution was obtained. 2N Sodium carbonate
25 solution (1.5 mL) was added and the mixture was purged with nitrogen. Bis(diphenylphosphino)ferrocenepalladium(II) chloride, dichloromethane complex (18 mg, 0.022 mmol) was added and the mixture was refluxed under nitrogen for 3 h. The mixture was diluted with water and extracted with ethyl acetate. The extract was concentrated. Silica gel chromatography (ethyl acetate
30 gradient to methanol/ethyl acetate (8:92)) provided the product (11) as a solid (0.13 g). APCI-MS Found [M+H]=396.

Step 10:

Conc. hydrogen chloride (1 mL) was added to a solution of the urea (11) (0.13 g, 0.33 mmol) in methanol (10 ml) and the solution was stirred at 23 °C for 5 30 min. The solvents were removed *in vacuo* and the residue was partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. The extract was concentrated to give a powder, which was triturated with diethyl ether, to leave 1-ethyl-3-(5-hydroxymethyl-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea, (12) as a powder (47 mg). HRFAB-MS Found: [M+H]=312.1457. C₁₆H₁₈N₅O₂ 10 requires 312.1460.


Steps 11 and 12:

Activated manganese dioxide (600 mg) was added to a solution of the 15 alcohol (12) (90 mg, 0.29 mmol) in a mixture of ethyl acetate (20 mL) and methanol (10 mL) and the mixture was stirred vigorously at 23 °C for 2 h. APCI-MS Found [M+H]=310. The reaction mixture was filtered through Celite, washing through with more ethyl acetate/methanol. The combined filtrates were concentrated to dryness to give the aldehyde, 1-Ethyl-3-(5-formyl-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea (13), which was used directly in the next step. 20 To a solution of the crude aldehyde (13) in methanol (20 mL) was added NaCN (75 mg, 1.53 mmol) and acetic acid (26 µL, 0.46 mmol). Activated manganese dioxide (600 mg) was added last and the mixture was stirred at 23 °C for 3 h, then filtered through Celite, washing through with more methanol. The combined 25 filtrates were concentrated to dryness to leave a solid which was adsorbed onto silica. Silica gel chromatography (ethyl acetate gradient to methanol/ethyl acetate (8:92)) provided 2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridine-5-carboxylic acid methyl ester (14) (36 mg). HRFAB-MS Found: [M+H]=340.1413. C₁₇H₁₈N₅O₃ requires 340.1410.

30

Example 8

Preparation of 1-Ethyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea




Step 1:

Compound 1 was prepared as described in the experimental provided for Example Number 6 (i.e. compound Number 9 of Example 6). Compound 1 (145 mg, 0.51 mmol) was suspended in toluene (9 mL), then a suspension of pyrimidine-5-boronic acid (96 mg, 0.77 mmol) in ethanol (2.5 mL) was added. 2 M Sodium carbonate (2.2 mL) was added and the flask placed under nitrogen. The catalyst Bis(diphenylphosphino)ferrocenepalladium(II) chloride, dichloromethane complex (23 mg, 0.03 mmol) was added last and the reaction mixture heated at reflux temperature for 2 h. thin layer chromatography (5% methanol/dichloromethane) at this point showed unreacted starting material, thus additional boronic acid (96 mg, 0.77 mmol) and catalyst (23 mg, 0.03 mmol) were added and the reaction heated at reflux for a further 3h., whereupon the reaction was complete by thin layer chromatography. After allowing the reaction to cool, all solvents were removed under reduced pressure to give a residue which was purified by chromatography on silica gel (2% methanol/dichloromethane), affording 1-ethyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea (2) as a solid after trituration with ethyl acetate (yield: 38 mg, 26%). HRMS (EI⁺) calcd C₁₄H₁₄N₆O (M⁺) 282.1229, found 282.1230.

Example 9

Preparation of 1-[7-(3,5-Dimethyl-isoxazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea

5




Using the general procedure of Example 8, but substituting the relevant starting material, 1-[7-(3,5-dimethyl-isoxazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea, was obtained as a solid. Mp 204-206 °C.

10

Example 10

Preparation of 1-[7-(1-Benzyl-1H-pyrazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea

15




Using the generalized procedure of Example 8, but substituting the relevant starting material, 1-[7-(1-benzyl-1H-pyrazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea was obtained as a solid following recrystallization. LCMS (APCI⁺) 361.2 (100%, MH⁺).

20

Example 11

Preparation of 1-Ethyl-3-[7-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-imidazo[1,2-a]pyridin-2-yl]-urea

25




Using the generalized procedure of Example 8, but substituting the relevant starting material, 1-ethyl-3-{7-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-imidazo[1,2-a]pyridin-2-yl}-urea was obtained HRMS (FAB⁺) calcd

5 C₂₀H₂₆N₇O (MH⁺) 380.2200, found 380.2192.

Example 12

Preparation of 1-Ethyl-3-[7-(1-methyl-1H-pyrazol-4-yl)-imidazo[1,2-

10 a]pyridin-2-yl]-urea




Using the general procedure of Example 8, but substituting the relevant
15 starting material, 1-ethyl-3-[7-(1-methyl-1H-pyrazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-urea was obtained. HRMS (FAB⁺) calcd C₁₄H₁₇N₆O (M⁺) 284.1386, found 284.1386.

Example 13

20

Preparation of 1-[7-(2,4-Dimethoxy-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea




Using the general procedure of Example 8, but substituting the relevant starting material 1-[7-(2,4-Dimethoxy-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea was obtained. LCMS (APCI⁺) 343.2 (100%, MH⁺).

5

Example 14

Preparation of 4-[2-(3-Ethyl-ureido)-imidazo[1,2-a]pyridin-7-yl]-3,5-dimethyl-pyrazole-1-carboxylic acid tert-butyl ester

10




15

Using the general procedure of Example 8, but substituting the relevant starting material, 4-[2-(3-Ethyl-ureido)-imidazo[1,2-a]pyridin-7-yl]-3,5-dimethyl-pyrazole-1-carboxylic acid tert-butyl ester was obtained LCMS (APCI⁺) 399.3 (100%, MH⁺).

Example 15

Preparation of 1-Ethyl-3-[7-(1H-pyrazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-urea

20




25

Using the general procedure of Example 8, but substituting the relevant starting material, the target compound 1-Ethyl-3-[7-(1H-pyrazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-urea was obtained. LCMS (APCI⁺) 271.1 (100%, MH⁺).

Example 16

Preparation of 1-(3-Chloro-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-3-ethyl-urea

5




Ethyl-3-(7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea (1) (196 mg, 0.70 mmol), prepared as in Example 1, was dissolved/suspended in tetrahydrofuran (80 mL) and cooled to 0°C (ice/water). *N*-chlorosuccinimide (102 mg, 0.77 mmol) was added and the mixture stirred at 0°C for 2h. All solids had dissolved and the reaction was complete by LCMS after this time. The solvent was removed under reduced pressure to give a residue which was purified by chromatography on silica gel (2% methanol/dichloromethane), followed by recrystallization from ethyl acetate/methanol to afford 1-(3-chloro-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-3-ethyl-urea (2) as a solid (132 mg). HRMS (EI⁺) calcd C₁₅H₁₄³⁵ClN₅O (M⁺) 315.0887, found 315.0882; calcd C₁₅H₁₄³⁷ClN₅O (M⁺) 317.0857, found 317.0862.

10

15

Example 17


20 Preparation of 1-[3-Chloro-7-(2-dimethylamino-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea



Using the general procedure of Example 16, but substituting the relevant starting material, [3-chloro-7-(2-dimethylamino-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea, was obtained. LCMS (APCI⁺) 360. HRMS (EI⁺) calcd C₁₆H₁₈³⁵ClN₇O (M⁺) 359.1261, found 359.1261; calcd C₁₆H₁₈³⁷ClN₇O (M⁺) 361.1232, found 361.1238.

Example 18

Preparation of 2-(3-Ethyl-ureido)-imidazo[1,2-a]pyridine-7-carboxylic acid methyl ester



Step 1:

2-Amino-4-methoxycarbonylpyridine (9.33 g, 61.4 mmol) (1) and *p*-tosyl chloride (12.35 g, 65.5 mmol) were heated at 90°C with stirring in pyridine (100 ml) for 2 hours. The solvent was then removed. Water (200 ml) was added to the residue and the resultant solid was removed by filtration and washed with water (2 x 50 ml) providing compound 2 (18.26 g). LCMS (APCI⁺): 307.1 [100 %].

Step 2:

Pyridine 2 (10.80 g, 65.6 mmol) and chloride 3 (18.26 g, 59.7 mmol) were dissolved in dimethyl formamide (100 ml) and diisopropylethylamine (11.4 ml,


65.6 mmol). The mixture stirred at 23 °C overnight. Dimethyl formamide was removed and the residue was dissolved in methanol (50 ml) then poured into water (400 ml). The precipitate was collected by filtration and washed with water (3 x 100 ml), 2:1 water:methanol (2 x 30 ml) then oven dried for 1 hour (110°).
 5 (22.6 g). LCMS (APCI⁺): 435.2 [100 %], 390.1 [25 %], 347.1 [40 %], 307.6 [35 %].

Step 3:

Concentrated sulfuric acid (200 ml) was added to the above mixture (20.5 g) and stirred at 23 °C for 20 minutes. The mixture was poured onto ice (~ 1500 g) and made basic (pH = 8) with 40 % sodium hydroxide(aq). The temperature was not allowed to exceed 15°C. The precipitated product 2-(3-Ethyl-ureido)-imidazo[1,2-a]pyridine-7-carboxylic acid methyl ester (**6**) was collected by filtration and washed with water (500 ml), then 2:1 water:methanol (2 x 50 ml) followed by drying (4 hours, 110°C). (10.27 g). (LCMS (APCI⁺): 263.2 [100 %], 192.1 [90 %].

Example 19

20 Preparation of 2-(3-Ethyl-ureido)-imidazo[1,2-a]pyridine-7-carboxylic acid amide




25 Ester **1** (0.79 g, 3.0 mmol), see Example 18, was heated in a sealed system for 4 days in ammonia methanol (7 N, 40 ml). After cooling to 23 °C the system was chilled in a freezer (-20°C) and then filtered to give compound **2** (0.66 g).
 LCMS (APCI⁺): 248.2 [100 %], 203.1 [30 %], 177.2 [65 %], 159.2 [15 %]

Example 20

Preparation of 1-Ethyl-3-[7-(5-methyl-2H-[1,2,4]triazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea

5



Step 1:


Dimethylacetamide dimethyl acetal (0.40 ml, 2.66 mmol) was added to 2-
 10 (3-ethyl-ureido)-imidazo[1,2-a]pyridine-7-carboxylic acid amide (as in Example
 19) (0.50 g, 2.0 mmol) then suspended in hot dimethylacetamide (~ 90°C) (6 ml).
 After 10 minutes heating was stopped and the mixture cooled to 23 °C. The
 mixture was diluted with water (60 ml) and extracted with dichloromethane (4 x
 15 ml). The combined extracts were then washed with water (30 ml), then brine
 solution (30 ml) and dried over sodium sulfate. The drying agent was removed by
 filtration and the resultant mixture was concentrated to provide 3 as a solid (0.58
 g). LCMS (APCI⁺): 317.2 [100 %], 246.2 [30 %].

Step 2:

Hydrazine hydrate (100μL, 2.05 mmol) was added to compound 3 (290.9
 20 mg, 0.92 mmol) dissolved in acetic acid (5 ml) and the mixture heated to 90°C for
 20 minutes. The mixture was concentrated and to the residue was added water (5
 ml) and 5 % potassium carbonate solution. The resulting solid was recovered by
 filtration and washed with water (2 x 5 ml) to give 1-ethyl-3-[7-(5-methyl-2H-
 25 [1,2,4]triazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea (4) (249 mg), which was
 subsequently recrystallized from dimethyl formamide/water. LCMS (APCI⁺):
 286.2 [100 %], 241.1 [30 %], 215.2 [25 %].

Example 21

Preparation of 1-[7-(1,5-Dimethyl-1H-[1,2,4]triazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea and 1-[7-(2,5-Dimethyl-2H-[1,2,4]triazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea




Methyl hydrazine (100 μ L, 1.88 mmol) was added to compound 3, produced as in Example 20, (241.0 mg, 0.77 mmol) dissolved in acetic acid (5 ml) and the mixture heated to 90°C for 30 minutes. The mixture was concentrated and to the residue was added water (5 ml) and 5 % potassium carbonate solution. The resulting solid was recovered by filtration and washed with water (2 x 5 ml) to give 1-[7-(1,5-dimethyl-1H-[1,2,4]triazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea 5 and 1-[7-(2,5-dimethyl-2H-[1,2,4]triazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea 6 (123.6 mg). LCMS (APCI⁺): 300.2 [100 %], 255.2 [25 %], 229.1 [30 %].

Example 22

20

Preparation of 1-Ethyl-3-[7-(5-methyl-[1,2,4]oxadiazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea



Step 1:

2-amino-4-methoxycarbonylpyridine (1) (0.77 g, 5.1 mmol) was heated overnight with stirring at 60°C in a sealed system with ammonia methanol (7 N, 20 ml). After cooling to 23 °C the solvent was removed by rotary evaporator to give compound 2 (0.7 g). LCMS (APCI⁺): 138.2 [100 %].

Step 2:

Compound 2 (0.70 g, 5.0 mmol) and *p*-tosyl chloride (2.45 g, 12.8 mmol) were heated at 90°C overnight with stirring in pyridine solution (25 ml). Solvent was removed and the residue treated with water (50 ml). Compound 3 precipitated and was collected by filtration and washed with water (10 ml). (1.31 g). LCMS (APCI⁺): 274.2 [100 %].

Step 3:

Hydroxylamine hydrochloride (0.55 g, 7.9 mmol) and potassium carbonate (0.55 g, 4.0 mmol) dissolved in water (10 ml) were added to compound 3 (1.00 g, 3.7 mmol) suspended in ethanol (40 ml). The mixture was heated to reflux with

stirring overnight. The mixture was then concentrated and the residue treated with water (30 ml). The precipitated solid (4) collected by filtration and washed with water (2 x 10 ml). (1.03 g). LCMS (APCI⁺): 307.1 [100 %].

5 **Step 4:**

Compound 4 (0.95 g, 2.65 mmol) was heated at reflux with stirring in triethylorthoacetate solution (2.5 ml) containing 2 drops of trifluoroborane diethylether complex for 1 hour. At this time another portion of triethylorthoacetate (0.5 ml) and trifluoroborane diethylether complex (2 drops)
10 were added and the mixture was stirred for an additional 0.5 hours. Ethanol (4 ml) was then added and the mixture cooled to 23 °C overnight. The precipitated solid (5) was collected by filtration and washed with ethanol (2 ml). (0.51 g). LCMS (APCI⁺): 331.1 [100 %].

15 **Step 5:**

Compound 6 (0.43 g, 1.7 mmol) was added as a solid to a suspension of compound 5 (0.50 g, 1.5 mmol) and diisopropylethylamine (0.30 ml, 1.7 mmol) in dimethyl formamide (5 ml). The mixture was stirred overnight at 23 °C. The reaction mixture was concentrated and the residue taken up in methanol (2 ml)
20 which was added to water (30 ml). The precipitated solid was collected by filtration and washed with water (2 x 5 ml) and water/methanol (1:1, 2 x 2ml). (0.68 g). LCMS (APCI⁺): 331.1 [100 %].


Step 6:

25 The mixture of step 5 (0.60 g) was stirred in concentrated sulfuric acid. (6 ml) until all had dissolved and then poured onto ice (~ 70 g) and made basic (pH = 9) with 40 % aqueous sodium hydroxide, maintaining the temperature below 20°C. The precipitated solid was collected by filtration and washed with water (100 ml), water/methanol (1:1, 10 ml) and methanol (5 ml) to give a solid (0.29
30 g). Recrystallization from dimethyl formamide gave target compound 9 as a solid (108.3 mg). LCMS (APCI⁺): 287.2 [100 %], 242.1 [25 %], 216.1 [40 %].

Example 23

Preparation of 1-Ethyl-3-[5-(1-methyl-1H-pyrazol-4-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea

5



Step 1:

A solution of 4-bromo-2,4-diaminopyridine (1) (1.09 g, 5.80 mmol) and ethyl bromopyruvate (0.85 mL of 90% purity, 6.09 mmol) in ethanol (100 mL) was refluxed for 3 h. The ethanol was removed *in vacuo* and the residue was slurried with saturated aqueous sodium bicarbonate, then diethyl ether to provide the product (2) as a powder (1.24 g, 75%). APCI-MS Found: [M+H]⁺=286, 284.

Step 2:

A solution of bromide (2) (1.11 g, 3.91 mmol), di-t-butylidicarbonate (1.87 g, 8.57 mmol) and N,N-dimethylaminopyridine (20 mg) in dry tetrahydrofuran (80 mL) was refluxed for 1h. The solvent was removed *in vacuo* residue was

partitioned between ethyl acetate and brine and worked up to give an oil which was chromatographed on silica. Elution with ethyl acetate/petroleum ether (1:1) gave product (3) as a viscous oil (1.31 g, 69 %), which was used directly. APCI-MS Found: $[M+H]^+=486, 484$.

5

Steps 3 and 4:

To a suspension of the bromide (3) (8.00 g, 0.016 mol) in toluene (120 mL) was added a suspension of pyridine-3-boronic acid (3.02 g, 0.024 mol) in
10 ethanol (30 mL) and the mixture was stirred for 5 min, by which time it was homogeneous. 2N Sodium carbonate (60 mL, 0.12 mol) was added and the mixture was purged with nitrogen. [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium II (0.26 g) was added last and the mixture was refluxed under nitrogen for 4 h. The mixture was partitioned
15 between ethyl acetate and water and the organic layer was worked up to give crude product (4) as an oil, which was immediately deprotected. APCI-MS Found: $[M+H]^+=483$.

The product was dissolved in a mixture of dichloromethane (100 mL) and
20 trifluoroacetic acid (50 mL) and the solution was refluxed for 1.5 h. The solvents were removed *in vacuo* and the residue was slurried with saturated aqueous sodium bicarbonate (200 mL) for 30 min. Diethyl ether (200 mL) was added and the mixture was slurried for a further 30 min and filtered. The solid was washed with several portions of diethyl ether and dried, to give product (5) as a powder
25 (3.74 g, 83%), sufficiently pure for the next step. APCI-MS Found: $[M+H]^+=283$.

Step 5:

A mixture of finely powdered amine (5) (4.00 g, 0.014 mol) and 4 N
30 hydrogen chloride (400 mL) was stirred vigorously at 23 °C for 30 min, by which time the hydrochloride salt had precipitated out as a yellow solid. The mixture was cooled to 5 °C and a solution of sodium nitrite (1.46 g, 0.021 mol) in water (5 mL)

was added drop wise. The mixture was stirred at this temperature for 30 min, then urea (0.59 g, 9.91 mmol) was added. The mixture was stirred at 23 °C for a further 1 h, then basified by portion wise addition of solid sodium bicarbonate. ethyl acetate was added and the mixture was stirred vigorously for 30 min, then filtered
5 through Celite to remove insoluble black material. The ethyl acetate layer was worked up, adsorbed onto silica and chromatographed. Ethyl acetate eluted foreruns, while ethyl acetate/methanol (95:5) gave the chloride (6) as a solid (1.21 g). APCI-MS Found: $[M+H]^+$ =304, 302.

10 **Step 6:**

To a solution of ester (6) (0.43 g, 1.41 mmol) in ethanol (40 mL) was added 3N potassium hydroxide (10 mL) and the solution was stirred at 23 °C for 3 h. After careful adjustment of the pH to 4 with conc. hydrogen chloride the
15 solution was concentrated to dryness. The residue was triturated with three 30 mL portions of methanol, filtered and the combined triturates were concentrated to dryness, leaving crude acid (7) as a white solid (0.55 g), contaminated with some salt. This material was used as such in the next step. APCI-MS Found: $[M-H]^-$ =274, 272.

20

Step 7:

To a solution of the crude acid (7) (0.55 g, 2.00 mmol) from step 6, and N,N-dimethylaminopyridine (ca. 5 mg) in dry dimethyl formamide (30 mL) was
25 added N,N-carbonyldiimidazole (0.49 g, 3.00 mmol) and the solution was stirred at 23 °C for 15 min. A solution of sodium azide (2 g) in water (10 mL) was added and the mixture was stirred vigorously for 30 min and then diluted with brine. The mixture was extracted with ethyl acetate and the extract washed well with brine, then worked up to give crude acyl azide as a cream solid. This was dissolved
30 immediately in dry t-butanol and refluxed under nitrogen for 8 h. Removal of the solvent *in vacuo* gave a solid which was adsorbed onto silica and chromatographed. Elution with ethyl acetate/methanol (92:8) gave the product (8)

as a white solid (0.38 g, 78% overall from ester (6)). APCI-MS Found:
[M+H]⁺=347, 345.

Step 8:

5

To a suspension of the chloride (8) (0.18 g, 0.52 mmol) in toluene (20 mL) was added a suspension of pyrazole-boronic (14) acid (0.16 g, 0.78 mmol) in ethanol (4 mL) and the mixture was stirred for 5 min, by which time it was homogeneous. 2N Sodium carbonate (2 mL, 4.0 mmol) was added and the mixture was purged with nitrogen. [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium II (20 mg) was added last and the mixture was refluxed under nitrogen for 24 h. The mixture was partitioned between ethyl acetate and water and the organic layer was worked up to give crude product (9) as an oil, which was adsorbed onto silica and chromatographed. Elution with ethyl acetate/methanol (95:5) gave foreruns, while ethyl acetate/methanol (9:1) eluted the product (9) as a white solid (0.10 g, 49 %). APCI-MS Found: [M+H]⁺=391.

Steps 9 and 10:

20

A solution of (9) (0.10 g, 0.26 mmol) in a mixture of dichloromethane (10 mL) and trifluoroacetic acid (10 mL) was refluxed for 1h and the solvents removed *in vacuo*. The residue was treated with saturated aqueous sodium bicarbonate, and extracted 6 times with ethyl acetate. The combined extract was worked up to give crude amine (10) as a yellow solid, which was used directly. APCI-MS Found: [M+H]⁺=291.

The amine (10) was dissolved in dry tetrahydrofuran (25 mL), ethyl isocyanate (0.11 mL, 1.39 mmol) was added and the solution was stirred at 23 °C for 72 h. The product was adsorbed directly onto silica by concentration *in vacuo* and chromatographed. Elution with ethyl acetate/methanol (9:1) gave foreruns while ethyl acetate/methanol (85:15) eluted product (11) as a yellow solid.


30

Crystallization from tetrahydrofuran/methanol/petroleum ether gave pure material (14 mg). APCI-MS Found: $[M+H]^+=362$.

Example 24

5

Preparation of 2-(3-Ethyl-ureido)-imidazo[1,2-a]pyridine-7-carboxylic acid




10 Step 1:

Compound 1, prepared as in Example 18, (2.62 g, 10 mmol) was stirred at 23 °C for 6 hours in a mixture of 1 N sodium hydroxide/methanol/tetrahydrofuran (100 mL of a 1:2:2 mixture). The reaction mixture was concentrated and the resultant residue was treated with 1N hydrogen chloride (25 ml) and water (10 ml). The precipitated solid was collected by filtration, washed with water (3 x 10 ml) and oven dried (110°C). Recrystallization from dimethyl formamide/water gives the target compound (2) as a powder (2.38 g). LCMS (APCI⁺): 249.2 [100 %], 204.1 [20 %], 178.2 [45 %].

20

Example 25

Preparation of 1-[7-(3,5-Dimethyl-1H-pyrazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea




Step 1:

To a solution of Compound (1), prepared as in Example 14, (83 mg, 0.208 mmol) in dry dichloromethane (10 mL) was added trifluoroacetic acid (10 mL), and the mixture was stirred at 23 °C for 4 h. The solvents were removed and the residue was treated with a mixture of ice and aqueous sodium bicarbonate (50 mL). The mixture was extracted with ethyl acetate (6x50 mL) and the combined extracts were concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (dichloromethane gradient to 5% methanol/dichloromethane), to give the target compound (2) (51 mg). LCMS (APCI⁺) 299.2 (100%, MH⁺).

Example 26

15

Preparation of 1-Ethyl-3-[7-(piperidine-1-carbonyl)-imidazo[1,2-a]pyridin-2-yl]-urea




Diethyl pyrocarbonate, DEPC, (0.17 ml, 0.97 mmol) was added by syringe to a suspension of compound (1), prepared as in Example 24, (218.3 mg, 0.88 mmol) and piperidine (0.18 ml, 2.45 mmol) in dimethylformamide (10 ml). The mixture was stirred overnight at 23 °C. The reaction mixture was concentrated then triturated with ethyl acetate. Compound (2) was recovered by filtration and

washed with ethyl acetate (1ml) and hexane (2 ml) (255.5 mg). LCMS (APCI⁺):
316.2 [100 %], 271.2 [10 %], 245.3 [35 %].

Example 27

5 Preparation of 1-Cyclopropyl-3-(7-bromopyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea



Step 1:

- 10 To a solution of 1 (7.2g, 23 mmol) in 50 mL dichloromethane and 5 mL triethylamine at 23 °C under a nitrogen atmosphere was added phenylchloroformate (5.0g, 32 mmol) drop wise. After 18 hours the reaction was diluted with diethylether (150 mL) and the precipitated product was collected by filtration, washed with water (50 mL) and dried under vacuum to give 2 (5.0 g).
- 15 MS (APCI) = 332.0, 334.0 [M+H]

Step 2:

- To a suspension of 2 (0.5g, 1.5 mmol) in dimethylsulfoxide (5 mL) at 23 °C under a nitrogen atmosphere was added an amine 3 (7.2 mmol) The reaction was heated to 80 °C until it became homogenous. The reaction was then diluted to 30 mL total volume with water and the precipitated product was collected by
- 20

vacuum filtration, washed twice with water (10 mL), diethyl ether (2 x 10 mL) and dried under vacuum to give the urea products **5** that were used crude in Step 3.


5 Step 3:

A suspension of **5** (0.76 mmol), pyrimidine-5-boronic acid (0.105g, 0.85 mmol), sodium carbonate (0.292g, 2.75 mmol), and [1,1'-Bis(diphenylphosphino)ferrocene] dichloropalladium(II) complex with dichloromethane (0.007g, 8.6 μ mol) in 6 mL of 7:3:2 dimethoxyethane/water/ethanol was heated for 30 minutes at 80 °C in a CEM microwave reactor. The reaction was acidified with 2 mL glacial acetic acid and evaporated in vacuo. The residue was purified by silica gel chromatography (gradient elution 0-50% isopropanol in dichloromethane) to give the target compound (**4**). MS(APCI) = 295.1 [M+H].

15

Example 28

Preparation of 1-Cyclopropylmethyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea




20

The compound was obtained using the method of Example 27 but substituting aminomethylcyclopropane in step 2. MS(APCI) = 309.3 [M+H].

25

Example 29

Preparation of 1-Propyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea




The compound was obtained using the method of Example 27 but substituting n-propylamine in step 2. MS(APCI) = 297.1 [M+H].

5

Example 30

Preparation of 1-Isopropyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea




10

The compound was obtained using the method of Example 27 but substituting isopropylamine in step 2. MS(APCI) = 297.1 [M+H].

Example 31


15 **Preparation of 1-(7-Pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-3-(2,2,2-trifluoro-ethyl)-urea**



20 The compound was obtained using the method of Example 27 but substituting (2,2,2-trifluoroethylamine hydrochloride (7.2 mmol) and triethylamine (1 mL, 7.2 mmol) in step 2. MS(APCI) = 337.1 [M+H].

Example 32

25 **Preparation of 1-(2-Methoxy-ethyl)-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea**




The compound was obtained using the method of Example 27, but substituting 2-methoxyethylamine in step 2. MS(APCI) = 285.0 [M+H].

5

Example 33

Preparation of 1-Cyclobutyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea



10

The compound was obtained using the method of Example 27 but substituting cyclobutylamine in step 2. MS(APCI) = 309.1 [M+H].

Example 34

15

The in-vitro antibacterial activity of selected compounds was determined against a strain of *Neisseria gonorrhoeae*, GC525 (NG-2888), which is described by Rouquette-Loughlin et al, in *Journal of Bacteriology*, Feb. 2003, p. 1101-1106, at p. 1103. In general, minimum inhibitory concentration (MIC)

20 susceptibility testing followed procedures recommended by the National Committee for Clinical Laboratory Standards (NCCLS¹⁻²) or followed the descriptions described below:

Bacterial Cultures

25

Neisseria gonorrhoeae strains were grown on Chocolate Agar II plates (BBL – Becton Dickinson Microbiology Systems, Cockeysville, MD) and incubated at 35°C in a humidified 5% CO₂ incubator (Forma Scientific, Marietta

OH). For microbroth dilution MIC testing, *N. gonorrhoeae* were tested in gonococcal broth (GCB):

Gonococcal Broth (GCB)³

| | |
|--------------------------------|---------|
| Proteose Peptone (BBL) | 15 g |
| Sodium Chloride | 5 g |
| Dipotassium Phosphate | 4 g |
| Potassium Dihydrogen Phosphate | 1 g |
| Soluble Starch (BBL) | 1 g |
| Sodium Bicarbonate | 420 mg |
| Distilled Water | 1000 mL |
| Isovitalex (BBL) | 10 mL |

5

Bacterial culture identifications were confirmed by standard microbiological methods.⁴ *N. gonorrhoeae* strains were streaked onto appropriate agar plates for visualization of purity and expected colony morphology. Gram stains were also utilized.

10

Permanent Stock Culture Collection

Bacterial stock cultures are stored as frozen suspensions at -70°C. *N. gonorrhoeae* cultures are suspended in inactivated Horse Serum (Colorado Serum Company, Denver, CO) containing 7.5% glucose prior to snap freezing in a dry ice/ethanol bath.

15

Preparation of Standardized Test Inocula and Plate Inoculation

Frozen stock cultures were used as the initial source of organisms for performing microbroth dilution MIC testing. Stock cultures were passed on their respective growth medium at least one growth cycle (18-24 hours) prior to their use. Bacterial culture suspensions were prepared directly from Chocolate Agar II plates into 10mL cation-adjusted Mueller-Hinton Broth (CAMHB, BBL, # BB215069). Before use, cultures were adjusted to an optical density value of 1.6-2 on a Perkin-Elmer Lambda EZ150 Spectrophotometer (Wellesley,

20

Massachusetts) set at a wavelength of 600nm. Random cultures were plated for validation of actual colony counts. The adjusted cultures were diluted 400-fold (0.25mL inoculum + 100 mL GCB) into gonococcal broth producing a starting inoculum of approximately 5×10^5 cfu/mL. These cultures were inoculated into

5 test plates (100 uL /well) using a Biomek® FX workstation (Beckman Coulter Inc., Fullerton, California). The inoculated plates were placed in stacks of no more than 4 and covered with an empty plate. Plates were incubated for 20-24 hours at 35°C in a humidified CO₂ incubator.

10 **Test Compound ("Drug") Preparation**

Drug stock solutions (2 mg/mL in DMSO) were prepared on the day of testing. Drugs were weight corrected for assay content where necessary.

15 **Drug Dilution Tray Preparation**

Microbroth dilution stock plates were prepared in two dilution series, 64-0.06 ug drug/mL and 1-0.001 ug drug/mL. For the high concentration series, 200 uL of stock solution (2 mg/mL) was added to duplicate rows of a 96-well plate. This was used as the first well in the dilution series. Serial two-fold decremental

20 dilutions were made using a BioMek FX robot (Beckman Coulter Inc., Fullerton, CA) with 10 of the remaining 11 wells, each of which contained 100 uL of the appropriate solvent/diluent. Row 12 contained solvent/diluent only and served as the control. For tube one of the low concentration series, 200 uL of a 31.25 ug/mL stock was added to duplicate rows of a 96-well plate. Serial two-fold dilutions

25 were made as described above.

Daughter plates were spotted (3.2 uL/well) from the stock plates listed above using the BioMek FX robot and were inoculated with organism (100 uL/well) as described previously.

30 **Reading the Test**

After incubation, the degree of growth in each well was read visually with the aid of a Test Reading Mirror (Dynatech Lab 220-16, Dynex Technologies,

Chantilly, VA). 96-well test plates are read in a darkened room with a single light shining from above. The MIC is the lowest concentration of drug that prevents macroscopically visible growth under the conditions of the test. Each drug dilution series was tested in duplicate; identical results are not always obtained. If

- 5 MIC values in duplicate tests differ by 1 well (two-fold), the lower value is reported. If duplicate tests vary by 2 dilutions (four-fold), the middle value is reported. Greater than a 4-fold MIC variance between duplicate tests invalidates the result and leads to a repeat of the organism/drug combination.

10 **References:**

- ¹ National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Fourteenth Informational Supplement. NCCLS document M100-S14 {ISBN 1-56238-516-X}, NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.
- 15 ² National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Tests for Bacteria That Grow Aerobically; Approved Standard-Sixth Edition. NCCLS document M7-A6 {ISBN 1-56238-486-4}, NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2003.
- 20 ³ Shapiro MA, Heifetz CL, Sesnie JC. Comparison of microdilution and agar dilution procedures for testing antibiotic susceptibility of *Neisseria gonorrhoeae*. J Clin Microbiol 1984;20:828-30.
- ⁴ Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Tenover FC, White
- 25 Clinical Microbiology, Eighth Edition. ASM Press {ISBN 1-55581-255-4}, American Society for Microbiology, 1752 N Street NW, Washington, DC 20036-2904 USA, 2003.

Results:

The following results were obtained:

| Example | MIC |
|---------|-------------|
| 1A | >64.0 ug/mL |
| 1B | 16.0 ug/mL |
| 2A | >64.0 ug/mL |
| 2B | 16.0 ug/mL |
| 3A | >64.0 ug/mL |
| 3B | 16.0 ug/mL |
| 4 | 12.7 ug/mL |
| 5 | >64.0 ug/mL |
| 6 | 45.3 ug/mL |
| 7A | 5.66 ug/mL |
| 7B | 0.500 ug/mL |
| 8 | 5.66 ug/mL |
| 9 | >64.0 ug/mL |
| 10 | 8.00 ug/mL |
| 11 | 64.0 ug/mL |
| 12 | 64.0 ug/mL |
| 13 | >64 ug/mL |
| 14 | 64 ug/mL |
| 15 | 64 ug/mL |
| 16 | 64 ug/mL |
| 17 | >32 ug/mL |
| 18 | >64 ug/mL |
| 19 | >64 ug/mL |
| 20 | >64 ug/mL |
| 22 | >64 ug/mL |
| 23 | 0.13 ug/mL |


| | |
|----|-----------|
| 24 | >64 ug/mL |
| 25 | 64 ug/mL |
| 27 | 64 ug/mL |
| 28 | 32 ug/mL |
| 29 | 16 ug/mL |
| 30 | 32 ug/mL |
| 31 | 64 ug/mL |
| 32 | >64 ug/mL |
| 33 | 16 ug/mL |

The invention and the manner and process of making and using it, are now described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the present invention and that modifications may be made therein without departing from the spirit or scope of the present invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification.

Claims

What is claimed is:


- 5 1. A compound of the formula




or a pharmaceutically acceptable salt thereof, wherein:

- 10 X₁ is CH₂, NH, or O;

X₂ is absent, or is

(CH₂)_{x'}, NH, O, or , wherein "wavy" are points of attachment, or

- 15 is a tether 2, 3 or 4 atoms in length, selected from



wherein R is H or (C₁-C₆)alkyl, and wherein "wavy" are points of attachment and x' is an integer from 1

- 20 to 3;

Y is N, C-H, C-F, or C-OMe;

R₁ is H or halo;

- 25

R₂ is (C₃-C₆)cycloalkyl,
(CH₂)_x-aryl,

(CH₂)_x-heterocyclo, or
 (CH₂)_x-heteroaryl,
 wherein x is 0, 1, or 2;

5

R₃ is H,

(C₁-C₆)alkyl,
 (C₃-C₆)cycloalkyl,
 aryl,
 heterocyclo,


10


heteroaryl,
 C(O)NR_aR_b,
 C(O)R_a,
 CO₂R_a,
 C(O)C(O)NR_aR_b,

15

NO₂,
 SO₂R_a,
 SO₂NR_aR_b,
 C(R_c)=NOR_a,
 C(R_c)=NR_a,

20

 , wherein "~~~~" indicates the point of attachment,

 , wherein "~~~~" indicates the point of attachment,
 and wherein

25

R_a is H,

(C₁-C₆)alkyl,
 (C₃-C₆)cycloalkyl,
 (CH₂)_y-aryl,
 (CH₂)_y-heterocyclo, or
 (CH₂)_y-heteroaryl,

30

wherein y is 0, 1, or 2;

R_b is H,

(C₁-C₆)alkyl,
(C₃-C₆)cycloalkyl,
5 aryl,
heterocyclo, or
heteroaryl;

R_c is H,

10 (C₁-C₆)alkyl,
(C₃-C₆)cycloalkyl,
aryl,
heterocyclo, or
heteroaryl; and

15 R₄ is (C₁-C₆)alkyl, (C₁-C₆alkyl)-O-(C₁-C₆alkyl), cyclopropyl, CH₂-
cyclopropyl, or cyclobutyl.

2. A compound according to claim 1 in which Y is N.

3. A compound according to claim 1 in which Y is C-H.

4. A compound according to anyone of claims 1-3 in which X₁ is NH,
X₂ is absent, or is (CH₂)_x, NH, or O;

R₁ is H;

R₂ is

(CH₂)_x-heteroaryl,

wherein x is 0, 1, or 2;

R₃ is

H,

aryl,

heterocyclo,
heteroaryl,
C(O)NR_aR_b,
C(O)R_a, or
CO₂R_a,

5

and,

- R₄ is (C₁-C₆)alkyl, cyclopropyl, CH₂-cyclopropyl or cyclobutyl.

10

5. A compound according to anyone of claims 1-4 in which R₂ is heteroaryl.

6. A compound according to anyone of claims 1-5 in which R₂ is heteroaryl and is selected from the group consisting of pyridine, and pyrimidine, either of which may be optionally substituted.

15

7. A compound according to anyone of claims 1-6 in which X₂ is absent and R₃ is hydrogen, heteroaryl, C(O)NR_aR_b, C(O)R_a, or CO₂R_a.

8. A compound according to anyone of claims 1-7 in which R₄ is ethyl or cyclobutyl.

20

9. A compound according to claim 1 selected from the group consisting of:

a. (7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-carbamic acid ethyl ester;

b. 1-ethyl-3-(7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea;

25

c. 1-[7-(2-dimethylamino-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-carbamic acid ethyl ester;

d. 1-[7-(2-dimethylamino-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;

30

e. [7-(6-methoxy-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-carbamic acid ethyl ester;

f. 1-ethyl-3-[7-(6-methoxy-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;

- g. 1-ethyl-3-[7-(2-methoxy-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- h. (7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl)-carbamic acid ethyl ester;
- 5 i. 1-ethyl-3-{7-[6-(2-morpholin-4-yl-ethoxy)-pyridin-3-yl]-imidazo[1,2-a]pyridin-2-yl}-urea;
- j. 1-ethyl-3-{7-[6-(2-morpholin-4-yl-ethoxy)-pyridin-2-yl]-urea};
- k. 1-ethyl-3-(5-hydroxymethyl-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 10 l. 1-ethyl-3-(5-formyl-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- m. 2-(3-ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridine-5-carboxylic acid methyl ester;
- n. 1-ethyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea
- 15 o. 1-[7-(3,5-dimethyl-isoxazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- p. 1-[7-(1-benzyl-1H-pyrazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- q. 1-ethyl-3-{7-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-imidazo[1,2-a]pyridin-2-yl}-urea;
- 20 r. 1-ethyl-3-[7-(1-methyl-1H-pyrazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- s. 1-[7-(2,4-dimethoxy-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- 25 t. 4-[2-(3-ethyl-ureido)-imidazo[1,2-a]pyridin-7-yl]-3,5-dimethyl-pyrazole-1-carboxylic acid tert-butyl ester;
- u. 1-ethyl-3-[7-(1H-pyrazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- v. 1-(3-chloro-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-3-ethyl-urea;
- 30 w. 1-[3-chloro-7-(2-dimethylamino-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;

- x. 2-(3-ethyl-ureido)-imidazo[1,2-a]pyridine-7-carboxylic acid methyl ester;
- y. 2-(3-ethyl-ureido)-imidazo[1,2-a]pyridine-7-carboxylic acid amide;
- z. 1-ethyl-3-[7-(5-methyl-2H-[1,2,4]triazol-3-yl)-imidazo
5 [1,2-a]pyridin-2-yl]-urea;
- aa. 1-[7-(1,5-dimethyl-1H-[1,2,4]triazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- bb. 1-[7-(2,5-dimethyl-2H-[1,2,4]triazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- 10 cc. 1-ethyl-3-[7-(5-methyl-[1,2,4]oxadiazol-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea; 1-ethyl-3-[5-(1-methyl-1H-pyrazol-4-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- dd. 2-(3-ethyl-ureido)-imidazo[1,2-a]pyridine-7-carboxylic acid;
- ee. 1-[7-(3,5-dimethyl-1H-pyrazol-4-yl)-imidazo[1,2-a]pyridin-2-yl]-
15 3-ethyl-urea;
- ff. 1-ethyl-3-[7-(piperidine-1-carbonyl)-imidazo[1,2-a]pyridin-2-yl]-urea;
- gg. 1-cyclopropyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 20 hh. 1-cyclopropylmethyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- ii. 1-propyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- jj. 1-isopropyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- kk. 1-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-3-(2,2,2-trifluoroethyl)-urea;
- 25 ll. 1-(2-methoxy-ethyl)-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea, and;
- mm. 1-cyclobutyl-3-(7-pyrimidin-5-yl-imidazo[1,2-a]pyridin-2-yl)-urea.
- 30 10. A compound according to claim 1 selected from the group consisting of

- a) 3-[2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-5-yl]-
[1,2,4]oxadiazole-5-carboxylic acid methanamide;
- 5 b) 1-{5-[5-(2-Dimethylamino-ethyl)-[1,2,4]oxadiazol-3-yl]-7-pyridin-
3-yl-imidazo[1,2-a]pyridin-2-yl}-3-ethyl-urea;
- c) 1-Ethyl-3-[5-(5-methoxy-[1,2,4]oxadiazol-3-yl)-7-pyridin-3-yl-
imidazo[1,2-a]pyridin-2-yl]-urea;
- 10 d) 1-Ethyl-3-[5-(3-methoxy-[1,2,4]oxadiazol-5-yl)-7-pyridin-3-yl-
imidazo[1,2-a]pyridin-2-yl]-urea;
- e) 1-Ethyl-3-[5-(3-methylamino-[1,2,4]oxadiazol-5-yl)-7-pyridin-3-
yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- 15 f) 1-Ethyl-3-{5-[5-(2-hydroxy-ethyl)-[1,3,4]oxadiazol-2-yl]-7-
pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl}-urea;
- g) 1-Ethyl-3-[5-(5-methyl-[1,3,4]oxadiazol-2-yl)-7-pyridin-3-yl-
imidazo[1,2-a]pyridin-2-yl]-urea;
- 20 h) 1-{5-[5-(2-Dimethylamino-ethyl)-[1,3,4]oxadiazol-2-yl]-7-pyridin-
3-yl-imidazo[1,2-a]pyridin-2-yl}-3-ethyl-urea;
- i) 1-Ethyl-3-[5-(5-methyl-[1,2,4]oxadiazol-3-yl)-7-pyridin-3-yl-
imidazo[1,2-a]pyridin-2-yl]-urea;
- 25 j) 1-Ethyl-3-[5-(5-methyl-[1,3,4]thiadiazol-2-yl)-7-pyridin-3-yl-
imidazo[1,2-a]pyridin-2-yl]-urea;
- 30 k) 1-Ethyl-3-{5-[5-(2-hydroxy-ethyl)-[1,3,4]thiadiazol-2-yl]-7-
pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl}-urea;

- l) 1-{5-[5-(2-Dimethylamino-ethyl)-[1,3,4]thiadiazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl}-3-ethyl-urea;
- 5 m) 2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridine-5-carboxylic acid methyl ester;
- n) 2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridine-5-carboxylic acid ethylamide;
- 10 o) 1-[5-(2-Dimethylamino-acetyl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- p) 1-Ethyl-3-(7-pyridin-3-yl-5-trifluoromethoxymethyl-imidazo[1,2-a]pyridin-2-yl)-urea;
- 15 q) 1-Ethyl-3-(5-propionyl-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea;
- r) 1-Ethyl-3-[5-(1-methylimino-propyl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- 20 s) 1-(5-Cyclopropanecarbonyl-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-3-ethyl-urea;
- 25 t) 1-[5-(Cyclopropyl-methoxyimino-methyl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-3-methyl-urea;
- u) 1-[5-Cyclopropanecarbonyl-7-(2-oxo-1,2-dihydro-pyridin-4-yl)-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- 30

- v) 1-Ethyl-3-[7-(2-oxo-1,2-dihydro-pyridin-4-yl)-5-propionyl-
imidazo[1,2-a]pyridin-2-yl]-urea;
- 5 w) 1-Ethyl-3-[5-(2-methanesulfonyl-ethyl)-7-pyridin-3-yl-
imidazo[1,2-a]pyridin-2-yl]-urea;
- x) 1-Ethyl-3-[5-(5-methyl-4H-[1,2,4]triazol-3-yl)-7-pyridin-3-yl-
imidazo[1,2-a]pyridin-2-yl]-urea;
- 10 y) 1-Ethyl-3-[5-(1-methyl-1H-pyrazol-4-yl)-7-pyridin-3-yl-
imidazo[1,2-a]pyridin-2-yl]-urea;
- z) 1-[5-(2-Dimethylamino-ethoxy)-7-pyridin-3-yl-imidazo[1,2-
a]pyridin-2-yl]-3-ethyl-urea;
- 15 aa) 1-Ethyl-3-[7-pyridin-3-yl-5-(2-[1,2,4]triazol-1-yl-ethoxy)-
imidazo[1,2-a]pyridin-2-yl]-urea;
- bb) 1-{5-[4-(2-Dimethylamino-ethyl)-thiazol-2-yl]-7-pyridin-3-yl-
imidazo[1,2-a]pyridin-2-yl}-3-ethyl-urea;
- 20 cc) N-Methyl-2-[2-(3-methyl-ureido)-7-pyridin-3-yl-imidazo[1,2-
a]pyridin-5-yloxy]-acetamide;
- dd) 1-Ethyl-3-[5-(6-hydroxy-pyridin-3-yl)-7-pyridin-3-yl-imidazo[1,2-
a]pyridin-2-yl]-urea;
- 25 ee) 1-{5-[4-(2-Dimethylamino-ethyl)-oxazol-2-yl]-7-pyridin-3-yl-
imidazo[1,2-a]pyridin-2-yl}-3-ethyl-urea;
- 30

- ff) 1-[5-(2-Dimethylamino-ethoxy)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-3-ethyl-urea;
- 5 gg) 1-Ethyl-3-[5-(2-pyrazol-1-yl-ethyl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- hh) 2-[2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-5-yl]thiazole-4-carboxylic acid amide;
- 10 ii) 1-Ethyl-3-[5-(2-oxo-2-pyridin-2-yl-ethyl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- jj) 1-Ethyl-3-[5-(2-oxazol-2-yl-ethyl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- 15 kk) 1-Ethyl-3-[5-(2-methylamino-pyrimidin-5-yl)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl]-urea;
- ll) 1-(5-Cyclopropyl-7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-3-ethyl-urea and
- 20 mm) N-{2-[2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-5-yl]-ethyl}-acetamide.
- 25 11. A compound which is selected from the group consisting of
- a) 3-[2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-5-yl]-[1,2,4]oxadiazole-5-carboxylic acid methylamide
- 30 b) 1-{5-[5-(2-Dimethylamino-ethyl)-[1,2,4]oxadiazol-3-yl]-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl}-3-ethyl-urea;


- c) 1-Ethyl-3-[5-(5-methoxy-[1,2,4]oxadiazol-3-yl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- 5 d) 1-Ethyl-3-[5-(3-methoxy-[1,2,4]oxadiazol-5-yl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- e) 1-Ethyl-3-[5-(3-methylamino-[1,2,4]oxadiazol-5-yl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- 10 f) 1-Ethyl-3-{5-[5-(2-hydroxy-ethyl)-[1,3,4]oxadiazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl}-urea;
- g) 1-Ethyl-3-[5-(5-methyl-[1,3,4]oxadiazol-2-yl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- 15 h) 1-{5-[5-(2-Dimethylamino-ethyl)-[1,3,4]oxadiazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl}-3-ethyl-urea;
- i) 1-Ethyl-3-[5-(5-methyl-[1,2,4]oxadiazol-3-yl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- 20 j) 1-Ethyl-3-[5-(5-methyl-[1,3,4]thiadiazol-2-yl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- k) 1-Ethyl-3-{5-[5-(2-hydroxy-ethyl)-[1,3,4]thiadiazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl}-urea;
- 25 l) 1-{5-[5-(2-Dimethylamino-ethyl)-[1,3,4]thiadiazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl}-3-ethyl-urea;
- 30 m) 2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidine-5-carboxylic acid methyl ester;

- n) 2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidine-5-carboxylic acid ethylamide;
- 5 o) 1-[5-(2-Dimethylamino-acetyl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-3-ethyl-urea;
- p) 1-Ethyl-3-(7-pyridin-3-yl-5-trifluoromethoxymethyl-imidazo[1,2-c]pyrimidin-2-yl)-urea;
- 10 q) 1-Ethyl-3-(5-propionyl-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl)-urea;
- r) 1-Ethyl-3-[5-(1-methoxyimino-propyl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- 15 s) 1-(5-Cyclopropanecarbonyl-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl)-3-ethyl-urea;
- 20 t) 1-[5-(Cyclopropyl-methoxyimino-methyl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-3-ethyl-urea;
- u) 1-[5-Cyclopropanecarbonyl-7-(2-oxo-1,2-dihydro-pyridin-4-yl)-imidazo[1,2-c]pyrimidin-2-yl]-3-ethyl-urea;
- 25 v) 1-Ethyl-3-[7-(2-oxo-1,2-dihydro-pyridin-4-yl)-5-propionyl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- w) 1-Ethyl-3-[5-(2-methanesulfonyl-ethyl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- 30

- x) 1-Ethyl-3-[5-(5-methyl-4H-[1,2,4]triazol-3-yl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- 5 y) 1-Ethyl-3-[5-(1-methyl-1H-pyrazol-4-yl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- z) 1-[5-(2-Dimethylamino-ethoxy)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-3-ethyl-urea;
- 10 aa) 1-Ethyl-3-[7-pyridin-3-yl-5-(2-[1,2,4]triazol-1-yl-ethoxy)-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- bb) 1-{5-[4-(2-Dimethylamino-ethyl)-thiazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl}-3-ethyl-urea;
- 15 cc) N-Methyl-2-[2-(3-methyl-ureido)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-5-yloxy]-acetamide;
- dd) 1-Ethyl-3-[5-(6-hydroxy-pyridin-3-yl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- 20 ee) 1-{5-[4-(2-Dimethylamino-ethyl)-oxazol-2-yl]-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl}-3-ethyl-urea;
- ff) 1-[5-(2-Dimethylamino-ethoxy)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-3-ethyl-urea;
- 25 gg) 1-Ethyl-3-[5-(2-pyrazol-1-yl-ethyl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- 30 hh) 2-[2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-5-yl]-thiazole-4-carboxylic acid amide;


- ii) 1-Ethyl-3-[5-(2-oxo-2-pyridin-2-yl-ethyl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- 5 jj) 1-Ethyl-3-[5-(2-oxazol-2-yl-ethyl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- kk) 1-Ethyl-3-[5-(2-methylamino-pyrimidin-5-yl)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl]-urea;
- 10 ll) 1-(5-Cyclopropyl-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl)-3-ethyl-urea, and;
- mm) N-{2-[2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-5-yl]-ethyl}-acetamide.
- 15

12. A compound which is:




(7-Pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-carbamic acid ethyl ester;


20




1-Ethyl-3-(7-pyridin-3-yl-imidazo[1,2-a]pyridin-2-yl)-urea;



[7-(2-Dimethylamino-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]
-carbamic acid ethyl ester;




5 1-[7-(2-Dimethylamino-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]-3
-ethyl-urea;




1-Ethyl-3-[7-(6-methoxy-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-urea;

10




[7-(6-Methoxy-pyridin-3-yl)-imidazo[1,2-a]pyridin-2-yl]-carbamic acid
ethyl ester; or




15

1-Ethyl-3-[7-(2-methoxy-pyrimidin-5-yl)-imidazo[1,2-a]pyridin-2-yl]
-urea.


20 13. A compound which is:



(7-Pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl)-carbamic acid ethyl ester;




5 1-Ethyl-3-(7-pyridin-3-yl-imidazo[1,2-c]pyrimidin-2-yl)-urea;




[7-(2-Dimethylamino-pyrimidin-5-yl)-imidazo[1,2-c]pyrimidin-2-yl]-carbamic acid ethyl ester;

10




1-[7-(2-Dimethylamino-pyrimidin-5-yl)-imidazo[1,2-c]pyrimidin-2-yl]-3-ethyl-urea;




15

1-Ethyl-3-[7-(6-methoxy-pyridin-3-yl)-imidazo[1,2-c]pyrimidin-2-yl]-urea;



[7-(6-Methoxy-pyridin-3-yl)-imidazo[1,2-c]pyrimidin-2-yl]-carbamic acid
ethyl ester; or



5

1-Ethyl-3-[7-(2-methoxy-pyrimidin-5-yl)-imidazo[1,2-c]pyrimidin-2-yl]-
urea.

14. A pharmaceutical formulation comprising a compound according to
10 anyone of claims 1-13 admixed with a pharmaceutically acceptable diluent,
carrier, or excipient.
15. A method of treating a bacterial infection in a mammal comprising
administering to a mammal in need thereof an effective amount of a compound
15 according to anyone of claims 1-13.
16. Use of a compound according to anyone of claims 1-13 as a medicine.
17. Use of a compound according to anyone of claims 1-13 in the manufacture
20 of a medicament for infectious disease.

ABSTRACT

Compounds of formula I and methods for their preparation are disclosed.
Further disclosed are methods of making biologically active compounds of
5 formula I as well as pharmaceutically acceptable compositions comprising
compounds of formula I. Compounds of formula I as disclosed herein can be used
in a variety of applications including use as antibacterial agents.

10

15